Vaccines and Global Health: The Week in Review
30 April 2022 :: Issue 655
Center for Vaccine Ethics & Policy (CVEP)

This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted and the elements of each edition are presented as a set of blog posts at https://centerforvaccineethicsandpolicy.net. This blog allows full text searching of over 23,000 entries.

Comments and suggestions should be directed to
David R. Curry, MS
Editor and
Executive Director
Center for Vaccine Ethics & Policy
david.r.curry@centerforvaccineethicsandpolicy.org

Request email delivery of the pdf: If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.

Support this knowledge-sharing service: Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click here toonate and thank you in advance for your contribution.

Contents [click to move among sections]
:: Coronavirus [COVID-19] - WHO
:: Organization Announcements
:: Journal Watch
UNICEF and WHO warn of ‘perfect storm’ of conditions for measles outbreaks, affecting children

Reported worldwide measles cases increased by 79 per cent in the first two months of 2022, compared to the same period in 2021, as WHO and UNICEF warn conditions ripe for serious outbreaks of vaccine-preventable illnesses.

NEW YORK/ GENEVA, 27 April 2022 – An increase in measles cases in January and February 2022 is a worrying sign of a heightened risk for the spread of vaccine-preventable diseases and could trigger larger outbreaks, particularly of measles affecting millions of children in 2022, warn WHO and UNICEF.

Pandemic-related disruptions, increasing inequalities in access to vaccines, and the diversion of resources from routine immunization are leaving too many children without protection against measles and other vaccine-preventable diseases.

The risk for large outbreaks has increased as communities relax social distancing practices and other preventive measures for COVID-19 implemented during the height of the pandemic. In addition, with millions of people being displaced due to conflicts and crises including in Ukraine, Ethiopia, Somalia and Afghanistan, disruptions in routine immunization and COVID-19 vaccination services, lack of clean water and sanitation, and overcrowding increase the risk of vaccine-preventable disease outbreaks.

Almost 17,338 measles cases were reported worldwide in January and February 2022, compared to 9,665 during the first two months of 2021. As measles is very contagious, cases tend to show up quickly when vaccination levels decline. The agencies are concerned that outbreaks of measles could also forewarn outbreaks of other diseases that do not spread as rapidly...

In 2020, 23 million children missed out on basic childhood vaccines through routine health services, the highest number since 2009 and 3.7 million more than in 2019...

...As countries work to respond to outbreaks of measles and other vaccine-preventable diseases, and recover lost ground, UNICEF and WHO, along with partners such as Gavi, the Vaccine Alliance, the partners of the Measles & Rubella Initiative (M&RI), Bill & Melinda Gates Foundation, and others are supporting efforts to strengthen immunization systems by:

- Restoring services and vaccination campaigns so countries can safely deliver routine immunization programmes to fill the gaps left by the backsliding;
- Helping health workers and community leaders communicate actively with caregivers to explain the importance of vaccinations;
- Rectifying gaps in immunization coverage, including identifying communities and people who have been missed during the pandemic;
- Ensuring that COVID-19 vaccine delivery is independently financed and well-integrated into overall planning for immunization services so that it is not carried out at the cost of childhood and other vaccination services;
- Implementing country plans to prevent and respond to outbreaks of vaccine-preventable diseases and strengthening immunization systems as part of COVID-19 recovery efforts.
1 in 4 children in Latin America and the Caribbean are exposed to diseases that can be prevented with vaccines

PANAMÁ CITY, 25 April 2022 – In five years, the complete vaccination schedule for diphtheria, tetanus and pertussis (DTP3) in Latin America and the Caribbean has dropped from 90 percent in 2015 to 76 percent in 2020, according to data from the Pan American Health Organization (PAHO) and UNICEF. This means that one in four children in the region has not received the full routine vaccination schedule that would protect them from multiple diseases.

The decrease in vaccination coverage precedes the pandemic; but the cessation or irregular programming of many primary health care services during the pandemic and people’s fear of catching COVID19 during visits to health centers is leaving many children without vaccines.

"The decline in vaccination rates in the region is alarming and puts millions of children and adolescents at risk of dangerous diseases that could be prevented," said Jean Gough, UNICEF Regional Director for Latin America and Caribbean. "The solution, and it has been proven to be effective: stronger vaccination programmes."

The 14 percentage point drop in vaccine coverage leaves nearly 2.5 million children without the complete DTP vaccination schedule and they are at risk of dangerous
preventable diseases. Of them, 1.5 million are “zero doses”: they have not even received the first dose of that vaccine.

**Dangerous setback**
The decrease in coverage exposes more children to the resurgence of preventable diseases and epidemiological outbreaks have already occurred. In example, while in 2013 only 5 people in the region got diphtheria, in 2018 almost 900 cases were registered, according to PAHO data. Measles sets higher alarms because it is caused by a highly contagious virus: in 2013 there were almost 500 cases; but in 2019, more than 23,000 people got the disease.

"**As countries recover from the pandemic, immediate actions are needed to prevent coverage rates from further dropping, because the re-emergence of disease outbreaks poses a serious risk to all of society,**" Gough said. "This is an opportunity to restructure primary health care and reinforce the comprehensive and community approach that bring vaccines to the most vulnerable populations. We cannot lose the efforts of past decades and let dangerous diseases threaten the lives of children."

**UNICEF calls on the governments of Latin America and the Caribbean to urgently re-establish and strengthen routine immunization programs**, develop campaigns to increase vaccine confidence and implement plans to reach all children and adolescents and their families; especially to the most vulnerable who do not have access to health services, due to their geographic location, migratory status or ethnic identity.

----

**Keynote Address: Breaking the Cycle of Neglect and Panic**
Date: April 27, 2022 Type: Speeches and Transcripts
We are meeting to discuss the issues of preparedness and response after more than two years of a global Pandemic. Although the situation has improved, we still need to be cautious given the case numbers in some countries and the low level of vaccination in some parts of the World.

The past two years have brought a lot of hardship: in terms lives lost, impacts on livelihoods and economic opportunities, and the impact on Human Capital through school closures and basic health services. This has further raised concerns about the state of preparedness of the world, and our collective ability to break the cycle of Panic and Neglect.

This is more urgent given what we know about the state of the world. In 2021, the Global Health Security Index showed the extent of the challenge with 70% of countries showed insufficient capacity to respond to health emergencies and deliver essential health services in clinics, hospitals, and community health centers. The pandemic revealed stark disparities in the capacity of countries to prevent and respond to COVID-19 bringing into sharp focus significant under-investments in pandemic preparedness which has amplified inequalities at all levels and highlighted the urgent need for collective action.

A recent Bank paper shows that most low- and middle-income countries are already facing tremendous fiscal pressures from the ongoing pandemic and will not be able to mobilize the huge sums necessary for investing in preparedness nor for strengthening their health systems.

To respond to these challenges the global community has shown a strong willingness to lean forward.

Indeed, the IDA20 replenishment, which was hosted by Japan, has culminated in a package which includes ambitious commitments to support countries to strengthen pandemic preparedness and response. The preparedness agenda is front and center of this IDA round.

The G20 and G7 have recently endorsed a new Financial Intermediary Fund (FIF) to strengthen preparedness and response. The FIF is meant to complement the current offerings and close remaining gaps in support of countries around the world.

Furthermore, there is broader and growing awareness of the One Health approach, which offers a framework to think about prevention and preparedness at country level. For instance, this is something that we are reflecting more and more in our World Bank portfolio through entry-points in the agriculture and environment sectors.

All of these efforts have to build on what we know works, and complement it in order to provide needed resources to countries who will have to address many gaps with limited fiscal space and competing needs. This requires collaboration and strong partnerships amongst all of us. No single actor or plan can do it alone.

This is where the Health Emergency Preparedness and Response Program is comes with its mission to catalyze, complement and connect. It has a critical role to play in the network of services and support we are building for our clients. I want here to thank Japan, Australia and Germany for their financing for and partnership in the HEPR program...
...Today’s session provides a valuable forum to delve deeper into the progress made through the HEPR Program funded efforts since the it was approved 18 months ago and the work ahead. It also affords an important opportunity to hear from leaders on the frontlines in countries and communities – essential voices from whom we must all learn as we chart the way forward.

Before I hand over to the team, I would like to leave with two thoughts:

:: First, we need to make strong analytical work at country and global levels a priority. Indeed, key indicators and analysis, as well as in depth work to understand country context will be important to guide policy and investments, but also raise the awareness on what is needed.

:: Second, although there is a momentum now around the agenda of preparedness, this can be sidelined very quickly by other emerging priorities. I count on all partners here to help make sure we maintain the push, and that we all advocate for preparedness to be streamlined throughout all aspects of the recovery.

I look forward to listening to our many partners and friends gathered here today for this event, from the Ministers of Health of Eswatini, Guyana, Togo, and partners from Japan, Australia, WHO and the Africa Center of Excellence for Genomics of Infectious Diseases.

::::::::::

COVID Vaccines - Humanitarian Buffer(HB)

“Broken” humanitarian COVID-19 vaccine system delays vaccinations - MSF

MSF Press Release 27 Apr 2022

- People in parts of northern Syria faced delays to receiving COVID-19 vaccinations earlier this year due to an unwieldy humanitarian vaccination system.
- The COVAX mechanism is failing the people it is meant to serve due to opaque legal frameworks and unfair liability demands.
- MSF urges the COVAX partners – who include WHO, UNICEF and Gavi – to immediately fix the system and enable people timely access to vaccines.

The COVID-19 vaccine Humanitarian Buffer(HB) is failing its mission to support people hit by the pandemic and struggling to access immunisation, says Médecins Sans Frontières (MSF). The HB is part of the COVAX mechanism*, whose aim is to assist groups of people who do not have access to COVID-19 vaccination in situations of humanitarian emergency. However, MSF’s recent experience in northern Syria has highlighted the system’s limitations and ultimate failure to fulfil its purpose.

In late 2021, when the Delta variant was still predominant, MSF teams observed a significant increase in the number of reported COVID-19 cases in Tell Abyad and Ras Al-Ain. The area, currently under Turkish control, is home to approximately 156,000 people, including almost 70,000 people in need according to the United Nations. Due to its status, the area is not included neither in the UN’s cross-border mechanism for the delivery of humanitarian aid, nor covered by the Syrian government’s national immunisation roll-out plan.

In November of the same year, MSF submitted an application to the UN-led humanitarian emergency COVID-19 vaccine reserve with a view to launching an immunisation campaign in collaboration with our
Syrian NGO partner, Al Ameen. However, once the application was approved approximately six weeks after its submission, MSF was confronted with an opaque, unwieldy legal framework placing an excessive liability on field-based humanitarian organisations carrying out the operations. This led to months of consuming contractual wrangling, until the Turkish authorities made alternative plans and the window closed on the opportunity for MSF and Al Ameen to run the planned immunisation campaign.

“For this system to work and allow for a timely intervention, it has to be practical and fair for all partners,” says Sarah Chateau, MSF’s Programme Manager for Syria. “When we started discussing with the rest of the COVAX partners, we realised it was definitely not the case.”

“To start with, we were denied access to some of the legal documents framing the procurement, which were necessary for us to assess the risks we were asked to accept,” explains Chateau.

Another significant obstacle was the deeply unbalanced distribution of liabilities in the initial version of the agreement framing the supply of the vaccines, which led to months of negotiations. In those agreements, UNICEF, Gavi (the global vaccine alliance) and the vaccine manufacturer transferred to MSF part of their liability for their own roles and responsibilities in the HB, requesting MSF to waive some of our legal avenues against them and, in some cases, indemnify them against their loss and third-party claims. Adding to this, the sheer number of contracts and interlocutors results in a lack of overall accountability for the overall functioning of the system.

As of March 2022, 2.5 million doses have been approved through the humanitarian buffer according to publicly available information and while more applications are in process, this is a small fraction of the 155 million doses announced at the beginning of 2022 as the HB target.

“The Humanitarian Buffer can potentially support millions of people, particularly among hard-to-reach groups of people,” says Chateau. “For the sake of our collective pandemic preparedness, we urge the COVAX partners to work to improve the system: unacceptably lengthy negotiations, excessive contractual complexity, lack of transparency and the unbalanced distribution of liabilities are issues that need an urgent solution.”

“We appreciate the concept of the HB,” says Chateau. “But the system today is failing its purpose and, more importantly, the people it is meant to serve.”

::::
::::
::::

**Coronavirus [COVID-19] - WHO**

*Public Health Emergency of International Concern (PHEIC)*

https://www.who.int/emergencies/diseases/novel-coronavirus-2019

**Weekly Epidemiological and Operational updates**

*Last update: 29 Apr 2022*

**Confirmed cases ::** 510 270 667
Confirmed deaths :: 6 233 526
Vaccine doses administered: 11 438 720 838

Weekly epidemiological update on COVID-19 - 27 April 2022

Overview
Globally, the number of new COVID-19 cases and deaths has continued to decline since the end of March 2022.

During the week of 18 through 24 April 2022, over 4.5 million cases and over 15 000 deaths were reported, decreases of 21% and 20% respectively, as compared to the previous week. However, an increase in the number of new weekly cases was reported from the Regions of the Americas (+9%) and the African Region (+32%), and the number of new weekly deaths increased in the South-East Asia Region (+41%), due to a delay in reporting of deaths from India, and in the Africa Region (+110%).

As of 24 April 2022, over 500 million confirmed cases and over six million deaths have been reported globally.

In this edition, we provide an update on the geographic distribution of circulating SARS-CoV-2 variants of concern (VOCs), including the prevalence and summary of current evidence of the Omicron variant. We also provide updates on vaccine effectiveness for the Delta and Omicron variants.

Figure 1. COVID-19 cases reported weekly by WHO Region, and global deaths, as of 24 April 2022**

Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process 02 April 2022
[New additions; Full scale view available at title link above]
[Updated on 30 Apr 2022]
COVID Vaccines/Therapeutics - Developer/Manufacturer Announcements
[Selected press releases/announcements from organizations from WHO EUL/PQ listing above and other organizations]

AstraZeneca  
**Press Releases** - No new digest announcements identified

**Bharat Biotech**  
**Press Releases**

*Apr 26: COVAXIN® for Children: India approves COVAXIN® in Children 6-12 years*
- COVAXIN is the one of the first COVID-19 vaccines in the world to generate data in 2-18 year age group.
- COVAXIN was earlier approved for children 12-18 years of age.
- Whole-Virion inactivated SARS-CoV-2 Vaccine (BBV152) has proven to be safe, well-tolerated, and immunogenic in paediatric subjects in phase II/III study in children 2-18 years of age.
- Neutralizing antibodies in children on were 1.7 times higher than in adults.
- No serious adverse event was reported. Pain at the injection site was the most commonly reported adverse event. No cases of myocarditis or blood clots were reported, as is to be expected with inactivated vaccines.
- COVAXIN exhibits robust immune responses in children with 2 doses and 6 months follow up, indicating durability of immune responses. Data was presented to the CDSCO Subject Expert Committee and will be published in the weeks to come.

Hyderabad, April 26, 2022: Bharat Biotech International Limited (BBIL), a global leader in vaccine innovation and developer of vaccines for infectious diseases, today announced that BBV152 (COVAXIN ®), its whole-virion inactivated COVID-19 vaccine candidate, has received emergency use approval in children 6-12 years of age...

**BioCubaFarma** – Cuba

**Últimas Noticias** - Website not leading at inquiry

**Biological E**

**News** -

*BE’s CORBEVAXTM Gets DCGI Nod for Emergency Use in 5-12 Years*
:: The approval comes soon after CORBEVAXTM was given the nod for 12-15-year group
:: As part of its Phase 2/3 clinical trials in 312 children aged between 5 and 12 years, Biological E administered two doses of 0.5 ml each of CORBEVAXTM or Placebo in 28 days’ gap
- April 26, 2022

**Biontech**

**Press Releases**

*Pfizer and BioNTech Submit Application for U.S. Emergency Use Authorization for a COVID-19 Vaccine Booster Dose in Children 5 Through 11 Years of Age*
26 April 2022

**CanSinoBIO**

**News** - Website not responding at inquiry
CIGB
Latest News - No new digest announcements identified

Cinagen
Recent News
Researchers announced safety and effectiveness of ReciGen (interferon beta-1a 44 mcg manufactured by CinnaGen Co.) on COVID-19 patients
20 June 2020

Clover Biopharmaceuticals - China
News - No new digest announcements identified

Curevac [Bayer Ag – Germany]
News - No new digest announcements identified

Gamaleya National Center
Latest News and Events - See Russia below.

IMBCAMS, China
Home - Website not responding at inquiry

Janssen/JNJ
Press Releases - No new digest announcements identified

Medicago
Media - No new digest announcements identified

Moderna
Press Releases
29 April, 2022
Moderna Files to Expand Conditional Marketing Authorization for Its COVID-19 Vaccine to Include Children Six Months to Under Six Years in The European Union

29 April, 2022
Moderna Finalizes Plan for Long-Term Strategic Partnership with The Government of Canada
:: Onshore manufacturing facility is expected to be based in Quebec and produce up to 100 million mRNA respiratory vaccine doses annually
:: The ten-year strategic partnership is expected to provide Canadians with rapid response capabilities to ensure future pandemic readiness

28 April, 2022
Moderna Files for Authorization of Its COVID-19 Vaccine in Young Children Six Months to Under Six Years of Age

Nanogen
News - No new digest announcements identified
FDA Announces Vaccines and Related Biological Products Advisory Committee Review of Novavax' COVID-19 Vaccine

NVX-CoV2373 would be the first protein-based COVID-19 vaccine to be reviewed by VRBPAC in the U.S.

GAITHERSBURG, Md., April 29, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) will review NVX-CoV2373 COVID-19 Vaccine (recombinant, adjuvanted) for active immunization against SARS-CoV-2 at a meeting scheduled for June 7, 2022.

Pfizer

Pfizer Shares Top-Line Results from Phase 2/3 EPIC-PEP Study of PAXLOVID™ for Post-Exposure Prophylactic Use

04.26.2022

Pfizer and BioNTech Submit Application for U.S. Emergency Use Authorization for a COVID-19 Vaccine Booster Dose in Children 5 Through 11 Years of Age

04.26.2022

Valneva and Pfizer Report Positive Phase 2 Pediatric Data for Lyme Disease Vaccine Candidate

R-Pharm

https://rpharm-us.com/index.php
[No news or media page identified]

Sanofi Pasteur

Press Releases - No new digest announcements identified

Serum Institute of India

NEWS & ANNOUNCEMENTS - No new digest announcements identified

Shifa Pharmed [Iran]
http://shafapharmed.com/
No news page identified.

Sinopharm/WIBPBIBP

News - No new digest announcements identified

Sinovac

Press Releases
China NMPA approved SINOVAC Omicron-specific vaccine for clinical trial
2022/04/26

Vector State Research Centre of Viralogy and Biotechnology
Home - No new digest announcements identified

WestVac Biopharma
Media - No new digest announcements identified

Zhifei Longcom, China
[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]
[No website identified]

::::

GSK
Press releases for media
29 April 2022
SK bioscience and GSK’s adjuvanted COVID-19 vaccine candidate meets coprimary objectives in a phase III study; Biologics License Application submitted for SKYCovione™(GBP510/GSK adjuvant) in South Korea

Merck
News releases - No new digest announcements identified

Novartis
News - No new digest announcements identified

SK Biosciences
Press Releases
SK bioscience and GSK’s Adjuvanted COVID-19 Vaccine Candidate Meets Coprimary Objectives in a Phase III Study; Biologics License Application Submitted for SKYCovione™(GBP510/GSK adjuvant) in South Korea
2022.04.29

SK bioscience Reports Positive Phase III Immunogenicity Results of Its Adjuvanted Covid-19 Vaccine Clinical Trial of COVID-19 Vaccine, AS03-adjuvanted
2022.04.25

Valneva
Press Releases
April 26, 2022
Valneva and Pfizer Report Positive Phase 2 Pediatric Data for Lyme Disease Vaccine Candidate

April 26, 2022
Valneva Provides Regulatory Update on its inactivated COVID-19 Vaccine Candidate
UNICEF COVID-19 Vaccine Market Dashboard :: Agreements Table Accessed 30 Apr 2022
An overview of information collected from publicly announced bilateral and multilateral supply agreements [no new agreements since 3/20/2022 reported]

<table>
<thead>
<tr>
<th><strong>36</strong></th>
<th>vaccines approved for use by at least one national regulatory authority</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>10</strong></td>
<td>vaccines in WHO’s Emergency Use Listing</td>
</tr>
<tr>
<td><strong>17.8bn</strong></td>
<td>doses secured globally</td>
</tr>
<tr>
<td><strong>$2–$40</strong></td>
<td>reported vaccine price range per dose</td>
</tr>
<tr>
<td><strong>2.8bn</strong></td>
<td>doses COVAX has secured, optioned, or received as donations</td>
</tr>
<tr>
<td><strong>1.44bn</strong></td>
<td>doses shipped through COVAX to 145 countries</td>
</tr>
</tbody>
</table>

COVID-19 Global Targets and Progress Tracker - IMF
The COVID-19 Global Targets and Progress Tracker presents a consolidated view of the progress towards global COVID-19 targets, barriers in access to COVID-19 tools, and delivery of donor pledges.

Daily Vaccination Rate Needed to Reach 70% by Mid-2022, assuming 2-dose vaccines (per 100 people)

The global targets presented in the Tracker are based on an alignment of the targets identified in the IMF Pandemic Proposal, ACT-A Strategic Plan & Budget, and the US-hosted Global C19 Summit, and as
such have been reaffirmed by multilateral institutions and global leaders. We will continue to enhance the tracker as we improve our data collection efforts.

Global Dashboard on COVID-19 Vaccine Equity

The Dashboard is a joint initiative of UNDP, WHO and the University of Oxford with cooperation across the UN system, anchored in the SDG 3 Global Action Plan for Healthy Lives and Well-being for All.

See also visualization on Vaccine Access and Vaccine Affordability

Global COVID-19 Access Tracker
https://www.covid19globaltracker.org/
The Race for Global COVID-19 Vaccine Equity

A flurry of nearly 200 COVID-19 vaccine candidates are moving forward through the development and clinical trials processes at unprecedented speed; more than ten candidates are already in Phase 3 large-scale trials and several have received emergency or limited authorization. Our team has aggregated and analyzed publicly available data to track the flow of procurement and manufacturing and better understand global equity challenges. We developed a data framework of relevant variables and conducted desk research of publicly available information to identify COVID vaccine candidates and status, deals and ongoing negotiations for procurement and manufacturing, COVID burden by country, and allocation and distribution plans. We have also conducted interviews with public officials in key countries to better understand the context and challenges facing vaccine allocation and distribution [accessed 24 July 2021]

See our COVID Vaccine Purchases research
See our COVID Vaccine Manufacturing research
See our COVID Vaccine Donations & Exports research

Overview of donations by top 10 donating countries

Bar chart is ordered by number of doses pledged. Donor charts are ordered by proportion of pledged donations shipped.
COVID-19 Data Explorer: Global Humanitarian Operations

COVID-19 Vaccine Roll-out
30 Apr 2022 | COVAX (WHO,GAVI,CEPI), UNDESA, Press Reports | DATA

Global COVID-19 Figures: 510M total confirmed cases; 6.2M total confirmed deaths

Global vaccines administered: 11.6B
Number of Countries: 28
COVAX Allocations Round 4-9 (Number of Doses): 170M
COVAX Delivered (Number of Doses): 290M
Other Delivered (Number of Doses): 300M
Total Delivered (Number of Doses): 590M
Total Administered (Number of Doses): 380M

https://data.covid19taskforce.com/data

A global effort to help developing countries access and deliver COVID-19 vaccines, testing, and therapeutics, as they work to end the pandemic and boost economic recovery.

The International Monetary Fund, World Bank Group, World Health Organization and World Trade Organization have joined forces to accelerate access to COVID-19 vaccines, therapeutics and diagnostics by leveraging multilateral finance and trade solutions, particularly in low- and middle-income countries.

Website accessed 30 Apr 2022: https://data.covid19taskforce.com/data The global view below is complemented by country-specific dashboards here.
*Our World in Data*

**Coronavirus (COVID-19) Vaccinations**  [Accessed 30 Apr 2022]

:: 65.4% of the world population has received at least one dose of a COVID-19 vaccine.

:: 11.59 billion doses have been administered globally, and 10.09 million are now administered each day.

:: Only 15.7% of people in low-income countries have received at least one dose.
U.S.: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

HHS
News
No new digest content identified.

BARDA-ASPR – U.S. Department of HHS [to 30 Apr 2022]
https://aspr.hhs.gov/newsroom/Pages/NewsRoomHome.aspx
News
ASPR funding expands manufacturing capacity for prefilled injectors to administer vaccines, medicines
Thursday, April 21, 2022

FDA
Press Announcements
April 25, 2022 - Coronavirus (COVID-19) Update: FDA Approves First COVID-19 Treatment for Young Children
Today, the U.S. Food and Drug Administration expanded the approval of the COVID-19 treatment Veklury (remdesivir) to include pediatric patients 28 days of age and older weighing at least 3 kilograms (about 7 pounds) with positive results of direct SARS-CoV-2 viral testing, who are:
:: Hospitalized, or
:: Not hospitalized and have mild-to-moderate COVID-19 and are at high risk for progression to severe COVID-19, including hospitalization or death.
This action makes Veklury the first approved COVID-19 treatment for children less than 12 years of age. As a result of today's approval action, the agency also revoked the emergency use authorization for Veklury that previously covered this pediatric population...

Regulatory Actions
Vaccines and Related Biological Products Advisory Committee- FDA
Calendar
April 29, 2022 - Coronavirus (COVID-19) Update: FDA Announces Tentative Advisory Committee Meeting Schedule Regarding COVID- 19 Vaccines
Today, the U.S. Food and Drug Administration is announcing its plans to hold virtual meetings of its Vaccines and Related Biological Products Advisory Committee (VRBPAC) in anticipation of complete submissions of emergency use authorization (EUA) requests in the coming months that have been publicly announced by COVID-19 vaccine manufacturers.

It is important to note that the dates below are tentative as none of the submissions are complete. The agency understands the urgency to authorize a vaccine for age groups who are not currently eligible for vaccination and will work diligently to complete our evaluation of the data. Should any of the
submissions be completed in a timely manner and the data support a clear path forward following our evaluation, the FDA will act quickly and anticipates convening the following VRBPAC meetings:

On June 7, FDA intends to convene VRBPAC to discuss an EUA request for a COVID-19 vaccine manufactured by Novavax to prevent COVID-19 in individuals 18 years of age and older.

On June 8, 21 and 22, the FDA has held dates for the VRBPAC to meet to discuss updates to the Moderna and Pfizer-BioNTech EUAs for their COVID-19 vaccines to include younger populations. As the sponsors complete their submissions and the FDA reviews that data and information, it will provide additional details on scheduling of the VRBPAC meetings to discuss each EUA request.

On June 28, the FDA plans to convene the VRBPAC to discuss whether the SARS-CoV-2 strain composition of COVID-19 vaccines should be modified, and if so, which strain(s) should be selected for Fall 2022. This meeting is a follow-up to the April 6 VRBPAC meeting that discussed general considerations for future COVID-19 vaccine booster doses and the strain composition of COVID-19 vaccines to further meet public health needs.

“As we continue to address the ongoing COVID-19 pandemic, there are a number of anticipated submissions and scientific questions that will benefit from discussion with our advisory committee members,” said Peter Marks, M.D., Ph.D., director of the Center for Biologics Evaluation and Research. “We are providing a tentative schedule for discussion of these submissions, as these meetings will cover a number of topics that are of great interest to the general public. The agency is committed to a thorough and transparent process that considers the input of our independent advisors and provides insight into our review of the COVID-19 vaccines. We intend to move quickly with any authorizations that are appropriate once our work is completed.”

Once the meeting dates are finalized, the FDA intends to make background materials available to the public, including the meeting agenda and committee roster, no later than two business days before each meeting...

::::::

White House [U.S.] [to 30 Apr 2022]  
*Briefing Room – Selected Major COVID Announcements*  
*Press Statement - COVID Context*  
Fact Sheet: Biden Administration Underscores Urgent Need for Additional COVID-19 Response Funding and the Severe Consequences of Congressional Inaction  
April 27, 2022 • Statements and Releases  

*Press Briefing by Press Secretary Jen Psaki and White House COVID-19 Response Coordinator Dr. Ashish Jha*  
April 26, 2022 • Press Briefings  

*FACT SHEET: Biden Administration Increases Access to COVID-19 Treatments and Boosts Patient and Provider Awareness*
Background Press Call by Senior Administration Officials on New Actions to Increase Access to COVID-19 Treatments and Boost Patient and Provider Awareness
April 25, 2022 • Press Briefings

USAID [to 30 Apr 2022]
Selected Press Releases, Statements, Announcements
The United States Provides an Additional $13.9 Million to Support Madagascar
April 29, 2022
The United States through the U.S. Agency for International Development (USAID) is providing an additional $13.9 million in funding to Madagascar. Of the $13.9 million in new funding, $5.4 million will go to the country’s COVID-19 response, and $8.5 million will support small and medium enterprises and economic empowerment for people with disabilities.

April 28, 2022
Statement by Administrator Samantha Power
I applaud the release of the historic 2022 U.S. Interagency Report on the Implementation of the Presidential Memorandum on Advancing the Human Rights of LGBTQI+ Persons Around the World. The report puts a timely spotlight on affirmative efforts of the U.S. government, in partnership with LGBTQI+ leaders, civil-society organizations, rights advocates, and a range of partners, to defend the human rights and dignity of LGBTQI+ persons in every region of the world and across sectors.

Biden Administration Announces Hundreds of Millions of Dollars in Global Food Aid to Respond to Putin’s Unprovoked Invasion of Ukraine
April 27, 2022
Today, the Biden Administration announced that the U.S. Agency for International Development (USAID) and the U.S. Department of Agriculture (USDA) are taking the extraordinary step to draw down the full balance of the Bill Emerson Humanitarian Trust (BEHT) as part of an effort to provide $670 million in food assistance to countries in need as a result of Putin’s unprovoked invasion of Ukraine. The world is suffering from historic levels of global food insecurity, which is being exacerbated by the impact Russia’s war on Ukraine is having on global food supplies. Available estimates suggest that an additional 40 million people could be pushed into poverty and food insecurity as a result of Russia’s aggression.

United States Providing More Than $200 Million in Additional Humanitarian Assistance for the Horn of Africa
April 26, 2022

Today in Geneva, the United States announced more than $200 million in additional assistance to respond to humanitarian needs in the Horn of Africa, including from the devastating drought and to address the needs of refugees, internally displaced persons, and conflict-affected population in the region. This assistance, through the U.S. Agency for International Development (USAID) and the U.S. Department of State will help save lives in Ethiopia, Kenya, and Somalia, where more than 20 million people are projected to need emergency food assistance this year following two years of inadequate rainfall in a region dependent on agriculture and livestock to survive.

Europe: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

**European Medicines Agency**

*News & Press Releases*

**Press Releases**

**News: European Immunization Week 2022: Statement by Executive Director Emer Cooke - Why vaccines contribute to a “Long Life for All” (new)**

Last updated: 25/04/2022

---

**European Centre for Disease Prevention and Control**


*Latest Updates [Selected]*

**Publication**

**Hepatitis of unknown origin - Reporting protocol 2022**

Technical guidance - 29 Apr 2022

This reporting protocol is intended for reporting national case-based data for surveillance of hepatitis of unknown origin from all the countries and areas of the WHO European Region, including the 27 countries of the European Union (EU) and the additional three countries of the European Economic Area (EEA), to the European level.

---

**European Centre for Disease Prevention and Control**

COVID-19 Vaccine Tracker

<table>
<thead>
<tr>
<th>Cumulative vaccine uptake (%) in the total population in EU/EEA countries</th>
</tr>
</thead>
<tbody>
<tr>
<td>At least one dose</td>
</tr>
<tr>
<td>-------------------</td>
</tr>
<tr>
<td>75.2%</td>
</tr>
</tbody>
</table>

Cumulative vaccine uptake (%) in the total population in EU/EEA countries as of 2022-04-29
European Commission
https://ec.europa.eu/commission/presscorner/home/en

Latest [Selected]
Statement 29 April 2022
Commission statement on the resignation of Fabrice Leggeri [Frontex]

Press release 28 April 2022
EU and international partners put forward a Declaration for the Future of the Internet
Today, the European Union, the United States, and several international partners have proposed a Declaration for the Future of the Internet, setting out the vision and principles of a trusted Internet.

Speech 27 April 2022 Brussels
Speech by Vice-President Jourová on abusive lawsuits against journalists and human rights defenders 'SLAPPs'

Press release 26 April 2022
Food security in Horn of Africa: EU steps up support to drought-affected countries
A devastating climate-induced drought is affecting the Horn of Africa. The situation is worsened by the impact of COVID-19, conflict and insecurity situation in the region, as well as the expected aggravation of food insecurity and nutrition due to Russia's invasion of Ukraine.

Press release 25 April 2022
Russian war crimes in Ukraine: Commission proposes to reinforce the mandate of Eurojust to collect and preserve evidence of war crimes
Today, the Commission has proposed to amend the Eurojust Regulation to give the Agency the legal possibility to collect, preserve and share evidence on war crimes.

Africa: COVID-19 – Announcements/Regulatory Actions/Deployment
https://africacdc.org/covid-19-vaccination/

<table>
<thead>
<tr>
<th>Vaccines received from COVAX</th>
<th>Vaccines received bilaterally</th>
<th>Vaccines received from AVATT</th>
</tr>
</thead>
<tbody>
<tr>
<td>51 Countries</td>
<td>52 Countries</td>
<td>38 Countries</td>
</tr>
</tbody>
</table>
Russia: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Russia: Sputnik V – *the first registered COVID-19 vaccine*
https://sputnikvaccine.com/newsroom/pressreleases/
Press Releases
Latest Updates [Selected]
[No new digest content identified; last announced at 28.03.2022]

India: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Ministry of Health and Family Welfare
https://www.mohfw.gov.in/

COVID-19 INDIA as on : 30 April 2022, 08:00 IST (GMT+5:30)
(↑↓ Status change since yesterday)

<table>
<thead>
<tr>
<th>Active</th>
<th>Discharged</th>
<th>Deaths</th>
</tr>
</thead>
<tbody>
<tr>
<td>18684 (0.04%)</td>
<td>42533377 (98.74%)</td>
<td>523803 (1.22%)</td>
</tr>
</tbody>
</table>

COVID-19 Vaccination as on : 30 April 2022, 08:00 IST (GMT+5:30)

Total Vaccination : 1,88,89,90,935 (22,58,059↑)
Government of India – Press Information Bureau

Latest Press Releases

COVID - 19 Vaccination Update - Day 470
:: India’s cumulative vaccination coverage crosses 189 Crore landmark milestone
:: More than 23 lakh Vaccine doses administered today till 7 pm

Posted On: 30 APR 2022 8:02PM by PIB Delhi

Indian Council for Medical Research (ICMR)
https://www.icmr.gov.in/media.html

Press Releases
No new digest content identified.

:::
:::
:::

China: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

[We did not identify official announcements about Shanghai confirming the reports below; See China CDC below for additional announcements]

Shanghai marks COVID milestone, Beijing on edge
By Brenda Goh and Min Zhang
- Shanghai records no COVID cases outside quarantine areas
- Beijing on tenterhooks, bracing for more restrictions
- Breakthrough would mark victory for Xi in crucial year
- Infections ease as China starts Labour Day holiday

SHANGHAI/BEIJING, April 30 (Reuters) - Shanghai said on Saturday it had detected no new daily COVID-19 cases outside quarantine areas, marking a milestone in its battle to contain the virus, which has paralysed the city of 25 million and put residents in the capital Beijing on edge.

Streets in Beijing were eerily quiet at the start of a five-day Labour Day break, with residents anxious that authorities would impose further restrictions during a holiday when many typically travel or socialise...

...Beijing will also implement a further two rounds of COVID tests on May 1 and May 3 in its most populous district of Chaoyang, known for its night life, malls and embassies.

The city will halt all restaurant dining between May 1 and 4, an official from the local commerce bureau said, calling for residents to "cook at home".

Officials have provided no timeline or strategy for returning to some semblance of normality.

Nomura estimates 46 cities are in full or partial lockdowns, affecting 343 million people. Societe Generale estimates that provinces experiencing significant restrictions account for 80% of China’s economic output.
In response to COVID and other headwinds, China will step up policy support for the economy, a top decision-making body of the Communist Party said on Friday, lifting stocks from two-year lows. [read more]

Shanghai reported 47 COVID-19 deaths for Friday, down from 52 a day earlier. Some have questioned the fatality rate, as many residents have said relatives or friends have died after catching coronavirus as early as March.

Beijing has reported 295 new COVID-19 cases since April 22, the local health authority said, of which 123 cases were found in the Chaoyang district.

Overall, mainland China reported 10,793 daily COVID-19 cases, down from 15,688 new cases a day earlier, the National Health Commission said on Saturday...

::::::

::::::

GPEI Polio

**Polio this week as of 27 April 2022**

*Headlines*

:: This week, Global Polio Eradication Initiative (GPEI) partners launched the *Investment Case* for polio eradication, at a virtual event. The Investment Case is the GPEI sister-document to the Polio Eradication Strategy 2022-2026, and outlines the humanitarian and economic benefits of polio eradication. During the event, the Government of Germany, which holds G7 presidency in 2022, announced that the country will co-host a pledging moment for the GPEI Strategy during the 2022 World Health Summit in October. A recording of the virtual event is available online [here](#).

:: Rotary International President Shekhar Mehta, WHO GPEI Director Aidan O’Leary and Dr Sarthak Das, Chief Executive Officer of the Asia Pacific Leaders Malaria Alliance offer their views on what lessons and experiences from polio and malaria can be drawn for existing and future pandemics, in an op-ed published in Health Policy Watch. Read it [here](#).

:: Comprehensive outbreak response in Tajikistan successfully stops outbreak: an outbreak response assessment concluded that a cVDPV2 outbreak that started in January 2021 has been stopped, thanks to comprehensive and rapid response with novel oral polio vaccine type 2 (nOPV2). [More](#)

**Summary of new polioviruses this week:**

– **Pakistan**: one WPV1 case and one positive environmental sample
– **DR Congo**: four cVDPV2 cases
– **Israel**: 13 cVDPV3 positive environmental samples
– **Nigeria**: one cVDPV2 case
– **Occupied Palestinian territory**: seven cVDPV3 positive environmental samples
– **Somalia**: one cVDPV2 case

**Polio transition planning and polio post-certification**

27 April 2022  *[Meeting report]*

*Overview*
The Executive Board at its 150th session noted an earlier version of this report.1 The present report provides an update on the implementation of the Strategic Action Plan on Polio Transition (2018–2023)2 at the start of 2022, within the context of the coronavirus disease (COVID-19) pandemic.

---

**UN OCHA – Current Emergencies**

**Current Corporate Emergencies**

*Afghanistan*

No new updates identified.

**Northern Ethiopia**

*Ethiopia - Northern Ethiopia Humanitarian Update Situation Report, 29 Apr 2022*

**HIGHLIGHTS**
- 3,400 MT of food brought into Tigray between 1 and 25 April. At least 4,675 MT of food are required every day to complete current food distribution by mid-May.
- More than 46,000 students across 144 schools in Wag Hemra Zone, South Wello, North Wello Oromia zones of Amhara Region received school feeding services during the reporting week.
- Some 16,500 IDPs in Amhara Region have been assisted with essential NFI kits during this reporting week.
- 82,884 people received food assistance in Fanti Raise and Kilbati Rasu zones in Afar during the reporting period and overall 698,503 people assisted as of 25 April.

**Ukraine**

*Ukraine: Humanitarian Impact Situation Report (As of 12:00 p.m. (EET) on 26 April 2022)*

---

**WHO & Regional Offices** [to 30 Apr 2022]

https://www.who.int/news

*News [Selected]*

29 April 2022

Statement

Quadripartite Memorandum of Understanding (MoU) signed for a new era of One Health collaboration

27 April 2022

Joint News Release

UNICEF and WHO warn of perfect storm of conditions for measles outbreaks, affecting children

[See Milestones above for detail]

27 April 2022

Departmental news

WHO launches a second report of country success stories in mitigating the impact of the COVID-19 pandemic on TB services
WHO Director General Speeches [selected]
https://www.who.int/director-general/speeches

Selected
27 April 2022
Speech
WHO Director-General's opening remarks at the 10th meeting of the Access to COVID-19 Tools Accelerator Facilitation Council - 26 April 2022

27 April 2022
Speech
WHO Director-General's remarks at the Investment Case for Polio Eradication – 26 April 2022

27 April 2022
Speech
WHO Deputy Director-General's speech at the OECD Council on the 2030 Agenda for Sustainable Development: Session 2: Global health challenges in the era of COVID-19

26 April 2022
Speech
WHO Director-General's opening remarks at the WHO press conference – 26 April 2022

25 April 2022
Speech
WHO Director-General's panel remarks at the Group of Friends of Global Health – 25 April 2022

25 April 2022
Speech
WHO Director-General's opening remarks at the Working Group on Sustainable Finance, final meeting – 25 April 2022

WHO Regional Offices
Selected Press Releases, Announcements

WHO African Region
:: 29 April 2022  Ghana finds success in COVID-19 mass vaccination campaigns
:: 29 April 2022  Speedy vaccination campaign helps stop cholera outbreak in Niger
:: 28 April 2022  Vaccine-preventable disease outbreaks on the rise in Africa

WHO Region of the Americas PAHO
:: 29 Apr 2022  Environmental surveillance - complementary tool for tracking COVID-19
Over 60 countries, including several in the Americas, are using wastewater monitoring to track SARS-CoV-2 in communities, with over 3,300 active sites. Washington, D.C., April 29, 2022 (PAHO) -- New guidance from the World Health Organization (WHO) provides advice to countries on sampling and testing for the SARS-CoV2 virus in untreated...

:: 25 Apr 2022
PAHO Director calls for immunization gaps to be closed for all vaccines, including COVID-19
2.7 million children in the Americas did not receive the vaccines needed to keep them healthy in 2020, while around 230 million people have still not received a single dose of COVID-19 vaccine in the region
Roseau, Dominica, 25 April 2022 (PAHO) – In 2020, 2.7 million children in the Americas did not receive the essential vaccines needed to keep...

:: 25 Apr 2022
World Malaria Day – More must be done to improve malaria response at the local level
Washington D.C., 25 April 2022 (PAHO) – On World Malaria Day, the Pan American Health Organization (PAHO) urges countries to step-up efforts to tackle malaria in the region, calling for prevention, diagnosis and treatment interventions that are data-led and tailored to local contexts. While in 2020, the 18 endemic countries of the Americas...

WHO South-East Asia Region SEARO
No new digest content identified.

WHO European Region EURO
:: WHO re-assigns Islands and Small States Institute in Malta as collaborating centre 29-04-2022
:: HPV vaccination brings the WHO European Region closer to a cervical cancer-free future 29-04-2022
:: Comprehensive outbreak response successfully stops spread of polio in Tajikistan 28-04-2022
:: Ukraine: Immediate steps needed to prevent a measles outbreak due to the ongoing war and low vaccination rates, warns WHO 28-04-2022
:: Countries across the WHO European Region celebrate World Health Day 2022 27-04-2022

WHO Eastern Mediterranean Region EMRO
:: WHO marks 5 years of strategic partnership with USAID in Iraq 26 April 2021

WHO Western Pacific Region
:: 25 April 2022  News release
WHO announces winners of inaugural Western Pacific Innovation Challenge

::::::

Disease Outbreak News (DONs)
Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health events or potential events of concern.
28 April 2022 | Ebola virus disease - Democratic Republic of the Congo

28 April 2022 | Japanese encephalitis - Australia

27 April 2022 | Multi-country outbreak of Salmonella Typhimurium linked to chocolate products – Europe and the United States of America
WHO Events
https://www.who.int/news-room/events/1
[Selected]
Indigenous peoples and tackling health inequities: WHO side event at the 21st session of the UN Permanent Forum on Indigenous Issues
3 May 2022 17:00 – 18:30 CET

Launch of the Child Health and Well Being Dashboard
4 May 2022 15:30 – 17:00 CET

New WHO Publications
https://www.who.int/publications/i
Selected Titles
28 April 2022
Integration of mental health and HIV interventions
28 April 2022
Emergency in Ukraine: external situation report #9, published 28 April 2022: reporting period: 21–27...

27 April 2022
Polio transition planning and polio post-certification
Overview
The Executive Board at its 150th session noted an earlier version of this report.1 The present report provides an update on the implementation of the Strategic Action Plan on Polio Transition (2018–2023)2 at the start of 2022, within the context of the coronavirus disease (COVID-19) pandemic.

27 April 2022
Strengthening pandemic preparedness planning for respiratory pathogens: policy brief, 27 April 2022
Overview
This policy brief outlines core elements that Member States are encouraged to a) develop an integrated approach to respiratory pathogen pandemic preparedness planning and b) enhance national and sub-national functional capacities for preparedness. In addition, this policy brief highlights suggested actions for Member States as they initiate or update national and sub-national pandemic preparedness planning process.
25 April 2022

25 April 2022
**WASH FIT: A practical guide for improving quality of care through water, sanitation and hygiene in health...**

25 April 2022
**Integrated care for older people (ICOPE) implementation pilot programme**

CDC/ACIP [U.S.] [to 30 Apr 2022]
http://www.cdc.gov/media/index.html
https://www.cdc.gov/vaccines/acip/index.html
**Transcript for CDC Media Telebriefing: Update on COVID-19**
Thursday, April 28, 2022

---

**ACIP Meetings**
Next ACIP Meeting
**June 22-23**
*No Agenda posted at inquiry*

---

**MMWR Weekly: Current Volume (71) April 29 2022 / No. 17**
PDF of this issue
- Public Health Actions to Control Measles Among Afghan Evacuees During Operation Allies Welcome — United States, September–November 2021
- Provisional COVID-19 Age-Adjusted Death Rates, by Race and Ethnicity — United States, 2020–2021
- Seroprevalence of Infection-Induced SARS-CoV-2 Antibodies — United States, September 2021–February 2022
- Notes from the Field: Response to Measles Among Persons Evacuated from Afghanistan — Joint Base McGuire-Dix-Lakehurst, New Jersey, August–October 2021

---

**Coronavirus Disease 2019 (COVID-19)- CDC**
Approximately 25 announcements/reports/data summaries.
:: 4/29/22  **Overall US COVID-19 Vaccine Distribution and Administration Update as of Fri, 29 Apr 2022 06:00:00 EST**

---
Africa CDC  [to 30 Apr 2022]
http://www.africacdc.org/
News
The Democratic Republic of Congo Declared Ebola Virus Disease (EVD) Outbreak in Mbandaka, Equateur Province
25 April 2022

China CDC
http://www.chinacdc.cn/en/

National Health Commission of the People's Republic of China  [to 30 Apr 2022]
http://en.nhc.gov.cn/
News
April 30: Daily briefing on novel coronavirus cases in China
On April 29, 31 provincial-level regions and the Xinjiang Production and Construction Corps on the Chinese mainland reported 1,424 new cases of confirmed infections.

National Medical Products Administration – PRC  [to 30 Apr 2022]
http://english.nmpa.gov.cn/
News
Nearly 3.34b COVID-19 vaccine doses administered on the Chinese mainland
2022-04-29
Nearly 3.34 billion COVID-19 vaccine doses had been administered on the Chinese mainland as of Wednesday, data from the National Health Commission showed Thursday.

CCDC Weekly Reports: Current Volume (4)
2022-04-29 / No. 17 OCCUPATIONAL CANCER ISSUE
View PDF of this issue

Contents  [click to move among sections]
:: Coronavirus [COVID-19] - WHO
:: Organization Announcements
:: Journal Watch
**Organization Announcements**

*Editor’s Note:*
Careful readers will note that the number and range of organizations now monitored in our *Announcements* section below has grown as the impacts of the pandemic have spread across global economies, supply chains and programmatic activity of multilateral agencies and INGOs.

**Airfinity**  [to 30 Apr 2022]
https://www.airfinity.com/insights

*INSIGHTS & COMPANY NEWS*
**Global sales estimate for COVID-19 antiviral pills increased by 60% to $32.5bn**
Published by Airfinity
Apr 21, 2022
Airfinity has released its latest COVID-19 treatments revenue forecast for Q1 2022 and 2022.

**Paul G. Allen Frontiers Group**  [to 30 Apr 2022]
https://alleninstitute.org/news-press/

*News*
**News from the Allen Institute: April 2022**
April 28, 2022
Highlights include: a new Lab Notes podcast on why we don't understand the brain, new research about how neurons connect, day-in-the-life features of our neuroscience labs and more.

**BMGF - Gates Foundation**  [to 30 Apr 2022]
https://www.gatesfoundation.org/ideas/media-center

*Press Releases and Statements*
No new digest content identified.

**Bill & Melinda Gates Medical Research Institute**  [to 30 Apr 2022]
https://www.gatesmri.org/news

The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world’s poorest people
No new digest content identified.

**CARB-X**  [to 30 Apr 2022]
https://carb-x.org/

*News*
No new digest content identified.

**Center for Vaccine Ethics and Policy – GE2P2 Global Foundation**  [to 30 Apr 2022]
https://centerforvaccineethicsandpolicy.net/
News/Analysis/Statements
:: Past weekly editions and posting of all segments of **Vaccines and Global Health: The Week in Review** are available here.

:: **Informed Consent: A Monthly Review – April 2022** is now posted here

:: **Statement on ICF [Informed Consent Form] Posting for Clinical Trials Involving Gene Editing/Gene Therapies - Invitation to Endorse**

:: **Patients, Politics, Pressure :: Pharma Stays Steady [Mostly] In Russia Sanctions Context Observations at 30 March 2022** David R Curry

**CEPI – Coalition for Epidemic Preparedness Innovations** [to 30 Apr 2022]
http://cepi.net/
Latest News
No new digest content identified.

**DARPA – Defense Advanced Research Projects Agency [U.S.]** [to 30 Apr 2022]
https://www.darpa.mil/news
News
No new digest content identified.

**Duke Global Health Innovation Center** [to 30 Apr 2022]
https://dukeghic.org/
Our Blog
No new digest content identified.

**EDCTP** [to 30 Apr 2022]
http://www.edctp.org/
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials
News
29 April 2022
**Belgium and Côte d’Ivoire join EDCTP Association**

25 April 2022
**World Malaria Day 2022: EDCTP supports innovative approaches to fight malaria**

**Emory Vaccine Center** [to 30 Apr 2022]
http://www.vaccines.emory.edu/
Vaccine Center News
Emory/Georgia funded TRAC by NIAID
NIH Funds New Tuberculosis Research Advancement Centers

European Vaccine Initiative  [to 30 Apr 2022]
http://www.euvsccine.eu/
Latest News, Events
"Vaccines provide everyone a chance at a fulfilling life"
World Immunization Week: 24 – 30 April 2022

Evidence Aid  [to 30 Apr 2022]
Evidence Aid aims to save lives and livelihoods in disasters by providing decision-makers with the best available evidence and by championing its use.
http://www.evidenceaid.org/
New Resources
Prophylactic anticoagulants for hospitalized COVID-19 patients (search up to 14 April 2021) Added April 25, 2022

Fondation Merieux  [to 30 Apr 2022]
http://www.fondation-merieux.org/
News, Events
Mérieux Foundation & University of Geneva co-organized event
22nd Advanced Vaccinology Course (ADVAC)
May 9 - 20, 2022 - Les Pensières Center for Global Health, Veyrier-du-Lac (France)

Gavi  [to 30 Apr 2022]
https://www.gavi.org/
News Releases
27 April 2022
Amref health Africa appointed by Gavi as the new Civil Society Organisation (CSO) host
- The Gavi CSO Constituency is a diverse group made up of over 4000 CSOs from around the world aimed at ensuring that every child and person is reached with immunisation.
- As Gavi CSO host, Amref will mobilise and support civil society organisations working to strengthen health systems and deliver immunisation services to underserved communities.
- Amref Health Africa is the first organisation located in a lower middle-income country to host the CSO platform

GHIT Fund  [to 30 Apr 2022]
https://www.ghitfund.org/newsroom/press
Press Releases
No new digest content identified.

Global Fund  [to 30 Apr 2022]
Global Fund Urges the World to Boost the Fight Against Malaria as COVID-19 Disruptions, Drug and Insecticide Resistance and New Threats Endanger Progress

Ahead of World Malaria Day, 25 April, the Global Fund calls for renewed commitment in the fight against malaria, a disease that now kills one child every minute. After years of steady declines, malaria cases and deaths are on the rise mainly due to s...

Global Research Collaboration for Infectious Disease Preparedness [GloPID-R] [to 30 Apr 2022]
https://www.gloid-r.org/news/
News
No new digest content identified

Hilleman Laboratories  [to 30 Apr 2022]
http://www.hilleman-labs.org/
News & Insights
No new digest content identified

HHMI - Howard Hughes Medical Institute  [to 30 Apr 2022]
https://www.hhmi.org/news
Press Room
No new digest content identified.

Human Vaccines Project  [to 30 Apr 2022]
http://www.humanvaccinesproject.org/
News
No new digest content identified.

IAVI  [to 30 Apr 2022]
https://www.iavi.org/
Latest News
No new digest content identified.

ICRC  [to 30 Apr 2022]
What’s New  [Selected]
Taking COVID-19 vaccines to remote areas in Mindanao

This is primarily because many are unable to bear the cost of travelling to a vaccine centre in the main city while others fear getting the vaccination owing to misinformation and lack of awareness. As a result, their families and communities remain v
ICRC appoints a new member to governing body

Geneva (ICRC) – At its meeting on 27 April, the Assembly of the International Committee of the Red Cross (ICRC) appointed Ms Samia Hurst-Majno as its newest member.

Table of National Committees and other national bodies on international humanitarian law

International Coalition of Medicines Regulatory Authorities [ICMRA]
Selected Statements, Press Releases, Research
No new digest content identified.

IFFIm
http://www.iffim.org/
Press Releases/Announcements
No new digest content identified.

IFRC  [to 30 Apr 2022]
Press Releases [Selected]
27/04/2022

Vaccinations vital as COVID cripples Pacific countries

Kuala Lumpur/Suva 28 April 2022 – The International Federation of Red Cross and Red Crescent Societies are increasingly concerned for more than 1 million people in Pacific nations as they struggle with their first major wave of COVID-19 fuelled by the Omicron variants.

Ramping up vaccinations is vital as the rapid surge in COVID infections is causing increasing death and illness in countries with low immunisation rates.

COVID-free for almost two years, Vanuatu, the Solomon Islands, Tonga, Kiribati, and Samoa have all experienced outbreaks in their capitals, and the virus is spreading to vulnerable outer island communities which lack basic treatment and vaccination facilities.

The virus is putting huge strains on fragile healthcare systems in population centres such as Honiara, Port Vila and Nuku’alofa. A rising number of healthcare workers are being struck down with COVID-19, further limiting health services and escalating the crisis...

26/04/2022

KwaZulu-Natal floods: Red Cross steps up response amid mounting humanitarian needs

Institut Pasteur  [to 30 Apr 2022]
Press Documents
No new digest content identified.
**IOM / International Organization for Migration** [to 30 Apr 2022]

*News - Selected*

*News Global*
29 April 2022

**IOM Appeals for USD 514 Million to Support Ukraine Response**

---

**ISC / International Science Council** [to 30 Apr 2022]
https://council.science/current/

*ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.*

*News* *Blogs* *Podcasts* *Events*

*Blogs*

**Vaccine promotion remains a key focus for this year’s Day of Immunology**
29.04.2022
On this International Day of Immunology, join ISC Member the International Union of Immunological Societies (IUIS) in celebrating the theme of vaccines with promotional and educational activities.

---

**International Union of Immunological Societies (IUIS)**
https://iuis.org/

*News/Events [Selected]*

**2022 International Day of Immunology**
April 26, 2022

---

**IVAC** [to 30 Apr 2022]
https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html

*Updates; Events*

*No new digest content identified.*

---

**IVI** [to 30 Apr 2022]
http://www.ivi.int/

*IVI News & Announcements*

*No new digest content identified.*

---

**Johns Hopkins Center for Health Security** [to 30 Apr 2022]
https://www.centerforhealthsecurity.org/news-center-news/

*Center News*

**Johns Hopkins Center for Health Security’s COVID-19 Testing Toolkit Launches New FAQs Tool**
April 28, 2022
**MSF/Médecins Sans Frontières** [to 30 Apr 2022]
http://www.msf.org/
*Latest [Selected Announcements]*
*Sudan*
*Violent attacks leave tens of thousands without access to healthcare in West Darfur*
Project Update 29 Apr 2022

*Access to medicines*
*“Broken” humanitarian COVID-19 vaccine system delays vaccinations*
Press Release 27 Apr 2022
[See Perspectives above for detail]

**National Academy of Medicine** - USA [to 30 Apr 2022]
https://nam.edu/programs/
*News [Selected]*
*NAM to Deliver National Plan to Strengthen Health Workforce Well-Being and Restore the Health of the Nation*
April 28, 2022
The National Academy of Medicine (NAM) Action Collaborative on Clinician Well-Being and Resilience is working urgently to develop a National Plan for health workforce well-being. The draft plan will be released in May 2022 for public input and builds on almost six years of collective work among 200 Clinician Well-Being Collaborative members and network organizations. […]

**National Academy of Sciences** - USA [to 30 Apr 2022]
*News*
No new digest content identified.

**National Vaccine Program Office** - U.S. HHS [to 30 Apr 2022]
https://www.hhs.gov/vaccines/about/index.html
*Upcoming Meetings/Latest Updates*
No new digest content identified.

**NIH** [to 30 Apr 2022]
http://www.nih.gov/
*News Releases*
No new digest content identified.

**OECD** [to 30 Apr 2022]
http://www.oecd.org/newsroom/publicationsdocuments/bydate/
*Newsroom/Library*
**OECD countries advancing slowly on sustainable development targets by 2030**

Despite progress made since the adoption of the 2030 Agenda for Sustainable Development and its 17 Goals (SDGs), OECD countries have met or are close to meeting only a quarter of the targets for which performance can be gauged, according to a new OECD report.

27 April 2022

**PATH** [to 30 Apr 2022]
https://www.path.org/media-center/
Press Releases
No new digest content identified.

**Sabin Vaccine Institute** [to 30 Apr 2022]
http://www.sabin.org/updates/pressreleases
Statements and Press Releases
No new digest content identified.

**UNAIDS** [to 30 Apr 2022]
http://www.unaids.org/en
Selected Press Releases/Reports/Statements
28 April 2022
**Key considerations to integrate HIV and mental health interventions**

**UNHCR** Office of the United Nations High Commissioner for Refugees [to 30 Apr 2022]
Selected News Releases, Announcements
No new digest content identified.

**UNICEF** [to 30 Apr 2022]
https://www.unicef.org/media/press-releases
Press Releases, News Notes, Statements [Selected]
Press release
04/27/2022
**UNICEF and WHO warn of ‘perfect storm’ of conditions for measles outbreaks, affecting children**
NEW YORK/ GENEVA, 27 April 2022 – An increase in measles cases in January and February 2022 is a worrying sign of a heightened risk for the spread of vaccine-preventable diseases and could trigger larger outbreaks, particularly of measles affecting millions of children in 2022, warn WHO and UNICEF. Pandemic-related disruptions, increasing...
[See Perspectives above for detail]

Press release
Global polio eradication initiative calls for renewed commitments to achieve promise of a polio-free world


GENEVA, 26 April 2022 – Today, the Global Polio Eradication Initiative (GPEI) announced that it is seeking new commitments to fund its 2022-2026 Strategy at a virtual event to launch its investment case. The strategy, if fully funded, will see the vaccination of 370 million children annually for the next five years and the continuation of global...

Press release

04/25/2022

1 in 4 children in Latin America and the Caribbean are exposed to diseases that can be prevented with vaccines


PANAMÁ CITY, 25 April 2022 – In five years, the complete vaccination schedule for diphtheria, tetanus and pertussis (DTP3) in Latin America and the Caribbean has dropped from 90 percent in 2015 to 76 percent in 2020, according to data from the Pan American Health [See Perspectives above for detail]

Unitedaid [to 30 Apr 2022]

https://unitaid.org/

Featured News

No new digest content identified.

Vaccine Equity Cooperative [nee Initiative] [to 30 Apr 2022]

https://vaccineequitycooperative.org/news/

News

No new digest content identified.

Vaccination Acceptance & Demand Initiative [Sabin] [to 30 Apr 2022]

https://www.vaccineacceptance.org/

Announcements, Blog

World Immunization Week 2022

Working Toward a Long Life for All with Dr. Ashmita Gupta and Dr. Salvia Zeeshan!

April 26, 2022

Vaccine Confidence Project [to 30 Apr 2022]

http://www.vaccineconfidence.org/

News, Research and Reports

No new digest content identified.
**Vaccine Education Center – Children's Hospital of Philadelphia** [to 30 Apr 2022]
http://www.chop.edu/centers-programs/vaccine-education-center

*News*
No new digest content identified.

**Wellcome Trust** [to 30 Apr 2022]
https://wellcome.ac.uk/news

*News, Opinion, Reports*
No new digest content identified.

**The Wistar Institute** [to 30 Apr 2022]

*Press Releases*
No new digest content identified.

**WFPHA: World Federation of Public Health Associations** [to 30 Apr 2022]
https://www.wfpha.org/

*Latest News - Blog*
No new digest content identified.

**World Bank** [to 30 Apr 2022]

*Selected News, Announcements*

**COVID-19 Vaccine Inequities and Hesitancy in Iraq**
Starting in August 2020, the World Bank collaborated with the World Food Programme (WFP) and implemented nine (9) rounds of the Iraq High Frequency Phone Survey (IHFPS) as part of the WFP's monthly mVAM...
Date: April 28, 2022 Type: Publication

**World Bank, Partners Launch New Fund to Spur Smart Investments in Childcare**
WASHINGTON, April 28, 2022—The World Bank and government and foundation partners today launched a new program to scale up quality, affordable childcare in developing countries – a critical investment to...
Date: April 28, 2022 Type: Press Release

**Keynote Address: Breaking the Cycle of Neglect and Panic**
We are meeting to discuss the issues of preparedness and response after more than two years of a global Pandemic. Although the situation has improved, we still need to be cautious given the case numbers...
Date: April 27, 2022 Type: Speeches and Transcripts
[See Week in Review above for detail]

**World Customs Organization – WCO** [to 30 Apr 2022]
World Organisation for Animal Health (OIE) [to 30 Apr 2022]
https://www.oie.int/en/media/news/
Press Releases, Statements
No new digest content identified.

WTO - World Trade Organisation [to 30 Apr 2022]
http://www.wto.org/english/news_e/news_e.htm
WTO News and Events [Selected]
Members discuss improving data collection on trade in essential goods to fight COVID-19
26 April 2022
The Committee on Market Access held on 26 April the second experience-sharing session on COVID-19-related goods, with members reporting on how they have monitored and measured trade in essential goods to combat the pandemic. They also discussed ways to improve data collection at a time of crisis. In addition, members explored how to promote greater international cooperation to better track the trade flows of value chains for the manufacturing of essential COVID-19-related products.

DG Okonjo-Iweala: Trade has central role in addressing food security challenges
26 April 2022
Record food prices and a worsening food security context have given new urgency to the role of trade in addressing the challenges we face today, Director-General Okonjo-Iweala said at a seminar on food security organized by the WTO on 26 April. In her opening remarks, she said the event provided an opportunity to deepen understanding of the issues at stake and to help members take concrete steps forward so that trade can contribute to the attainment of food security around the world.

ARM [Alliance for Regenerative Medicine] [to 30 Apr 2022]
Selected Press Releases
Alliance for Regenerative Medicine Announces CEO Transition
April 27, 2022  WASHINGTON, DC
    Janet Lynch Lambert will step down as the CEO of the Alliance for Regenerative Medicine after guiding the leading international advocacy organization for cell, gene and tissue-engineered therapies through five years of extraordinary growth in membership, funding, and influence. In Lambert’s time as the CEO of ARM, the membership doubled to more than 425 diverse global members and the organization’s budget and full-time staff tripled...The ARM board has constituted an 8-person Search Committee to conduct the search for a CEO successor, and Lambert is a key member of that committee. Executive search firm Catalyst Advisors, led by Partner Gilbert Forest, has been retained to support the search....
BIO Statement on USTR Special 301 Report

April 29, 2022

USTR this week released its 2022 Special 301 Report. BIO, after reviewing the report, released the following statement:

“We welcome USTR’s efforts to address IP-related concerns for U.S.-based biotech enterprises in China, especially concerning China’s coercive technology transfer policies, patent prosecution, and patent enforcement obstacles. USTR’s emphasis on monitoring China's progress in implementing its Phase One Agreement commitments to address these longstanding IP matters is encouraging...”

DCVMN – Developing Country Vaccine Manufacturers Network [to 30 Apr 2022]
http://www.dcvmn.org/
News; Upcoming events
No new digest content identified.

ICBA – International Council of Biotechnology Associations [to 30 Apr 2022]
https://internationalbiotech.org/news/
News
No new digest content identified.

IFPMA [to 30 Apr 2022]
http://www.ifpma.org/resources/news-releases/
Selected Press Releases, Statements, Publications
Celebrating World IP Day with a focus on youth and innovation
26 April 2022

International Generic and Biosimilar Medicines Association [IGBA]
https://www.igbamedicines.org/
News
No new digest content identified.

International Alliance of Patients’ Organizations – IAPO [to 30 Apr 2022]
https://www.iapo.org.uk/news/topic/6
Press and media [Selected]
No new digest content identified.

PhRMA [to 30 Apr 2022]
http://www.phrma.org/
Latest News [Selected]
No new digest content identified.
Journal Watch

Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

AJOB Empirical Bioethics
Volume 13, 2022 Issue 2
https://www.tandfonline.com/toc/uabr21/current
Article
Ethical Reasoning During a Pandemic: Results of a Five Country European Study
Pages: 67-78
Published online: 09 Mar 2022

Article
Governing Gene Drive Technologies: A Qualitative Interview Study
N. de Graeff, Karin R. Jongsma, Jeantine E. Lunshof & Annelien L. Bredenoord
Pages: 107-124
Published online: 03 Jul 2021

AMA Journal of Ethics
Volume 24, Number 4: E249-341 Apr 2022
https://journalofethics.ama-assn.org/issue/health-equity-us-latinx-communities
Health Equity in US Latinx Communities
Latinx communities in the US include over 60 million people with a plurality of political beliefs, cultural practices, and wealth. This diversity is also expressed in population health data: some health indicators suggest advantages of Latinx community membership while other data demonstrate inequitable
disease burden and maldistribution of environmental and occupational risk. Legacies of colonial conquest of the Americas persist in discrimination and marginalization today and are embodied by members of our Latinx communities.

American Journal of Infection Control
April 2022  Volume 50  Issue 4  p367-476
http://www.ajicjournal.org/current
[Reviewed earlier]

American Journal of Preventive Medicine
April 2022  Volume 62  Issue 4  p473-660
https://www.ajpmonline.org/current
[Reviewed earlier]

American Journal of Public Health
April 2022  112(52)
http://ajph.aphapublications.org/toc/ajph/current
Supplement 2 2022 = Global Opioid Crisis

American Journal of Tropical Medicine and Hygiene
Volume 106 (2022): Issue 2 (Feb 2022)
https://www.ajtmh.org/view/journals/tpmd/106/2/tpmd.106.issue-2.xml
[Reviewed earlier]

Annals of Internal Medicine
March 2022  Volume 175, Issue 3
http://annals.org/aim/issue
[Reviewed earlier]

Artificial Intelligence – An International Journal
Volume 305  April 2022
[Reviewed earlier]

BMC Cost Effectiveness and Resource Allocation
http://resource-allocation.biomedcentral.com/
(Accessed  30 Apr 2022)
[No new digest content identified]

BMJ Global Health
Integrated delivery of family planning and childhood immunisation services: a mixed methods assessment of service responsiveness

Postpartum women represent a considerable share of the global unmet need for modern contraceptives. Evidence suggests that the integration of family planning (FP) with childhood immunisation services could hel...

Authors: Jessie K. Hamon, Misozi Kambanje, Shannon Pryor, Alice S. Kaponda, Erick Mwale, Helen E. D. Burchett, Susanah H. Mayhew and Jayne Webster

Citation: BMC Health Services Research 2022 22:572
Content type: Research Published on: 28 April 2022

Robustness analysis for quantitative assessment of vaccination effects and SARS-CoV-2 lineages in Italy

In Italy, the beginning of 2021 was characterized by the emergence of new variants of SARS-CoV-2 and by the availability of effective vaccines that contributed to the mitigation of non-pharmaceutical intervent...

Authors: Chiara Antonini, Sara Calandrini and Fortunato Bianconi

Citation: BMC Infectious Diseases 2022 22:415
Content type: Research Published on: 29 April 2022

Circulating vaccine derived polio virus type 1 outbreak, Saadah governorate, Yemen, 2020

Yemen has faced one of the worst humanitarian crises in the world since the start of the war in 2015. In 2020; 30 Vaccine Derived Polio Virus type 1 (VDPV1) isolates were detected in Saadah governorate. The ai...

Authors: Mutahar Ahmed Al-Qassimi, Mohammed Al Amad, Labiba Anam, Khaled Almoayed, Ahmed Al-Dar and Faten Ezzadeen

Citation: BMC Infectious Diseases 2022 22:414
Content type: Research Published on: 29 April 2022

Exploration of attitudes regarding uptake of COVID-19 vaccines among vaccine hesitant adults in the UK: a qualitative analysis

The aim of this work was to explore barriers and facilitators to uptake of COVID-19 vaccines and to explore views and reactions to efforts to improve vaccine uptake among vaccine hesitant individuals. 

Authors: Sarah Denford, Fiona Mowbray, Lauren Towler, Helena Wehling, Gemma Lasseter, Richard Amiòt, Isabel Oliver, Lucy Yardley and Matthew Hickman

Citation: BMC Infectious Diseases 2022 22:407
Content type: Research Published on: 26 April 2022
Predictors of COVID-19 vaccine acceptability among health professions students in Vietnam

The COVID-19 vaccine hesitancy or refusal has actually been a threat to global health. In the current situation, health professions students are at risk for SARS-CoV-2 infection during their internship at health care facilities, and their vaccination is essential. Therefore, this study aimed to identify predictors associated with COVID-19 vaccine acceptability among health science students in Vietnam. A total of 727 health science students were surveyed. The results showed that the most significant predictors of vaccine acceptance were gender, knowing someone who received the vaccine, and the belief that the vaccine is effective against COVID-19. The study also highlighted the need for targeted interventions to increase COVID-19 vaccine acceptance among health science students.

What are the reasons for refusing a COVID-19 vaccine? A qualitative analysis of social media in Germany

Vaccination against COVID-19 has been available in Germany since December 2020. However, about 30% of the population report not wanting to be vaccinated. In order to increase the willingness of the population to get vaccinated, it is important to understand the reasons behind this refusal. This study aimed to analyze why people in Germany are refusing the COVID-19 vaccine, using data from social media. The analysis revealed that the main reasons for refusal were concerns about vaccine safety, lack of trust in the government, and prioritization of other health issues. The study concluded that targeted interventions are needed to address these concerns and increase vaccine acceptance.

Pentavalent vaccination in Kenya: coverage and geographical accessibility to health facilities using data from a community demographic and health surveillance system in Kilifi County

There is substantial evidence that immunization is one of the most significant and cost-effective pillars of preventive and promotive health interventions. Effective childhood immunization coverage is thus essential. This study aimed to assess the coverage and geographical accessibility of pentavalent vaccination in Kilifi County, Kenya, using data from a community demographic and health surveillance system. The results showed that vaccination coverage was low, and there were significant geographical disparities in accessibility to health facilities. The study recommended improving the vaccination program and increasing access to health facilities in remote areas.
**A tool for early estimation of influenza vaccination coverage in Spanish general population and healthcare workers in the 2018–19 season: the Gripómetro**

Electronic vaccine registries are not yet widely established. There is a need to real-time monitor influenza vaccine coverage, which may raise awareness to risk groups and professionals, and eventually allow t...

Authors: Javier Díez-Domingo, Esther Redondo Margüello, Raúl Ortiz de Lejarazu Leonardo, Ángel Gil de Miguel, José María Guillén Ortega, Jesús Rincón Mora and Federico Martinón-Torres

Citation: BMC Public Health 2022 22:825
Content type: Research Published on: 25 April 2022

**Factors related to parents’ adherence to childhood immunization**

Immunizations protect children from deadly infectious diseases. Yet, there is still insufficient understanding of the factors associated with parents’ non-adherence to immunizations in contexts outside of West...

Authors: Fatimah Hobani and Eman Alhalal

Citation: BMC Public Health 2022 22:819
Content type: Research Published on: 25 April 2022

**BMC Research Notes**

[Accessed 30 Apr 2022]

**Improving the reproducibility and integrity of research: what can different stakeholders contribute?**

Increasing awareness of problems with the reproducibility and integrity of research led the UK Parliament Science and Technology Committee to launch, in July 2021, an inquiry into reproducibility and research ...

Authors: Malcolm Macleod

Citation: BMC Research Notes 2022 15:146
Content type: Commentary Published on: 25 April 2022
Therapeutic Innovations in Neuroscience

The theme of this issue of Clinical Pharmacology & Therapeutics (CPT) encompasses neuroscience in the broad sense to include neurology and psychiatry, nonclinical and clinical aspects, novel clinical trial methodologies, and modeling and simulation approaches applicable to central nervous system (CNS) drug development and therapy. While naturally the last two years have been dominated by coronavirus disease 2019 (COVID-19), it is important not to forget that drug development for other indications has not been stopped, albeit many trials were affected in terms of delays in recruitment and collection of clinical data.

Clinical Therapeutics

March 2022 Volume 44 Issue 3 p349-472
http://www.clinicaltherapeutics.com/current

Original Research

Rolling Reviews During COVID-19: The European Union Experience in a Global Context
Roelie Marinus, Sarah Mofid, Marya Mpandzou, Thomas C. Kühler
Published online: January 09, 2022
p352-363
Open Access

Reviews

Leah Burns, Nadege Le Roux, Robert Kalesnik-Orszulak,...Mathias Hukkelhoven, Frank Rockhold, John O'Donnell
Published online: February 15, 2022
p420-437
Commentaries

Beyond Influenza Vaccination: Expanding Infrastructure for Hospital-based Pediatric COVID-19 Vaccine Delivery
Annika M. Hofstetter, Suchitra Rao, Ravi Jhaveri
Published online: January 26, 2022
p450-455

Clinical Trials
Volume 19 Issue 2, April 2022
https://journals.sagepub.com/toc/ctja/19/2
[Reviewed earlier]

Conflict and Health
http://www.conflictandhealth.com/
[Accessed 30 Apr 2022]
[No new digest content identified]

Contemporary Clinical Trials
Volume 114 March 2022
[Reviewed earlier]

The CRISPR Journal
Volume 5, Issue 2 / April 2022
https://www.liebertpub.com/toc/crispr/5/2
[Reviewed earlier]

Current Genetic Medicine Reports
Volume 9, issue 4, December 2021
https://link.springer.com/journal/40142/volumes-and-issues/9-4
[Reviewed earlier]

Current Opinion in Infectious Diseases
April 2022 - Volume 35 - Issue 2
https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx
[Reviewed earlier]

Current Protocols in Human Genetics
Volume 108, Issue 1 December 2020
Ethics & Human Research
Volume 44, Issue 2  Pages: 1-40  March–April 2022
https://onlinelibrary.wiley.com/toc/25782363/current
Consent and decisional capacity; Outside experts and IRBs; Therapeutic misconception
[Reviewed earlier]

Ethics & International Affairs
Winter 2021 (35.4) | December 2021
https://www.ethicsandinternationalaffairs.org/2021/winter-2021-35-4/
TABLE OF CONTENTS
[Reviewed earlier]

Ethics, Medicine and Public Health
Volume 21 (April 2022)
[New issue; No digest content identified]

The European Journal of Public Health
Volume 32, Issue 2, April 2022
https://academic.oup.com/eurpub/issue/32/2
[Reviewed earlier]

Expert Review of Vaccines
Vol 21 (4) 2022
https://www.tandfonline.com/toc/ierv20/current
[Reviewed earlier]

Forum for Development Studies
Volume 49, 2022 - Issue 1
http://www.tandfonline.com/toc/sfds20/current
[Reviewed earlier]

Genome Medicine
https://genomemedicine.biomedcentral.com/articles
[Accessed 30 Apr 2022]
[No new digest content identified]
COMMENTARIES

Open Access

End Malaria Faster: Taking Lifesaving Tools Beyond “Access” to “Reach” All People in Need
Courtney Emerson, Jed Meline, Anne Linn, Julie Wallace, Bryan K. Kapella, Meera Venkatesan and Richard Steketee
Global Health: Science and Practice April 2022, 10(2):e2200118; https://doi.org/10.9745/GHSP-D-22-00118

To “reach the unreached” with preventive and curative malaria services, we must know which individuals and communities remain unreached and then bring tailored services from the clinic to the community and home.

Community Health Workers in Pandemics: Evidence and Investment Implications
Madeleine Ballard, Ari Johnson, Iris Mwanza, Hope Ngwira, Jennifer Schechter, Margaret Odera, Dickson Nansima Mbewe, Roseline Moenga, Prossy Muyingo, Ramatulai Jalloh, John Wabwire, Angela Gichaga, Nandini Choudhury, Duncan Maru, Pauline Keronyai, Carey Westgate, Sabitri Sapkota, Helen Elizabeth Olsen, Kyle Muther, Stephanie Rapp, Mallika Raghavan, Kim Lipman-White, Matthew French, Harriet Napier and Lyudmila Nepomnyashchyi
Global Health: Science and Practice April 2022, 10(2):e2100648; https://doi.org/10.9745/GHSP-D-21-00648

Community health workers have long played a critical role in preventing, detecting, and responding to pandemics across the globe. To expand, improve, and institutionalize these services, changes in the approach to bi/multilateral aid and private philanthropic investments in low- and middle-income countries are required.

VIEWPOINTS

Open Access

Strategies to Promote Health System Strengthening and Global Health Security at the Subnational Level in a World Changed by COVID-19
Martin Allilio, Neetu Hariharan, Elizabeth Lugten, Kama Garrison, Rhea Bright, Wilberforce Owembabazi, Uwem Inyang, Saad El-Din Hassan and Kelly Saldana
Global Health: Science and Practice April 2022, 10(2):e2100478; https://doi.org/10.9745/GHSP-D-21-00478

Structural weaknesses in national health systems have led to huge variations in responses to COVID-19. This calls for a unified approach to health security and essential health services as public health threats and the expectation for health care systems to provide improved access and services at affordable cost increases.

ORIGINAL ARTICLES
Open Access

Cost of Delivering Tetanus Toxoid and Tetanus-Diphtheria Vaccination in Vietnam and the Budget Impact of Proposed Changes to the Schedule
Vu Quynh Mai, Laura Boonstoppel, Kelsey Vaughan, Carl Schutte, Annette Ozaltin, Duong Thi Hong, Nguyen Mai Khanh, Hoang Manh Thang, Tran Tuan Anh and Hoang Van Minh
Global Health: Science and Practice April 2022, 10(2):e2100482; https://doi.org/10.9745/GHSP-D-21-00482

This study shows that replacing tetanus toxoid vaccination in Vietnam for girls aged 15–16 years in high-risk areas with routine tetanus-diphtheria vaccination for children aged 7 years mainly through a school-based delivery strategy will likely result in immunization cost savings.

Global Legal Monitor – Library of Congress/USA
https://www.loc.gov/collections/global-legal-monitor/
[Accessed 30 Apr 2022]
[No new digest content identified]

Global Public Health
Volume 17, Issue 5 (2022)
http://www.tandfonline.com/toc/rgph20/current

Review Article
What makes global healthcare partnerships successful? A systematic review
Regan Guilfoyle, Alexander D. Morzycki & Abdullah Saleh
Pages: 662-671
Published online: 09 Mar 2021

ABSTRACT
Academic communities are increasingly involved in efforts to address the overwhelming burden of disease in low-middle income countries. There is, however, little research dedicated to understanding the best approach to creating a successful and sustainable global healthcare project. Our objective was to review the shared characteristics of successful healthcare partnerships between high- and low-middle income countries. Two independent reviewers conducted a systematic review. Articles, describing collaborative, healthcare partnerships between a high- and low-middle income countries between 1910 and September 2018, were included. Twenty-six articles were included. The majority of collaborations were initiated by either the host institution or as a joint decision between institutions. The primary goal of these collaborations revolved around medical education/training and curriculum development. Two partnerships, after more than a decade of collaboration, had achieved a self-sustaining programme. Lack of funding was identified as a major barrier to sustainability. Successful global healthcare partnerships require true collaboration and equal participation of all partners. Funding should be secured prior to programme development in anticipation of a minimum 10-year project. A minimum list of guidelines has been proposed to improve the chances of both a successful and sustainable collaboration.

Globalization and Health
http://www.globalizationandhealth.com/
[Accessed 30 Apr 2022]
[No new digest content identified]
Seroprevalence and risk factors of COVID-19 in healthcare workers from 11 African countries: a scoping review and appraisal of existing evidence
Sophie Alice Müller, Rebekah Ruth Wood, Johanna Hanefeld, Charbel El-Bcheraoui
Health Policy and Planning, Volume 37, Issue 4, April 2022, Pages 505–513,
https://doi.org/10.1093/heapol/czab133

A systematic review of scope and quality of health economic evaluations conducted in Ethiopia
Daniel Erku, Amanuel G Mersha, Eskinder Eshetu Ali, Gebremedhin B Gebretekle, Befikadu L Wubishet
Health Policy and Planning, Volume 37, Issue 4, April 2022, Pages 514–522,
https://doi.org/10.1093/heapol/czac005

What makes working together work? A scoping review of the guidance on North–South research partnerships
Shirine Voller, Joanna Schellenberg, Primus Chi, Nicki Thorogood
Health Policy and Planning, Volume 37, Issue 4, April 2022, Pages 523–534,
https://doi.org/10.1093/heapol/czac008

Health Research Policy and Systems
http://www.health-policy-systems.com/content
[Accessed 30 Apr 2022]
[No new digest content identified]
**Humanitarian Practice Network**
https://odihpн.org/
*Featured Publications*
[No new digest content identified]

**Human Vaccines & Immunotherapeutics** (formerly Human Vaccines)
Volume 18, Issue 1, 2022
https://www.tandfonline.com/toc/khvi20/current
[Reviewed earlier]

**Immunity**
Apr 12, 2022 Volume 55 Issue 4 p575-734
https://www.cell.com/immunity/current
[New issue; No digest content identified]

**Infectious Agents and Cancer**
http://www.infectagentscancer.com/
[Accessed 30 Apr 2022]
[No new digest content identified]

**Infectious Diseases of Poverty**
http://www.idpjournапl.com/content
[Accessed 30 Apr 2022]
[No new digest content identified]

**International Health**
Volume 14, Issue 2, March 2022
https://academic.oup.com/inthealth/issue/14/2
[Reviewed earlier]

**International Human Rights Law Review**
Volume 10 (2021): Issue 2 (Dec 2021)
https://brill.com/view/journals/hrlr/10/2/hrlr.10.issue-2.xml
[Reviewed earlier]

**International Journal of Community Medicine and Public Health**
Vol 9, No 1 (2022) January 2022
https://www.ijcmph.com/index.php/ijcmph/issue/view/84
[Reviewed earlier]
Table of Contents

The role of social media in promoting citizenship values of international students during the COVID-19 global health crisis
Thelal Iqab Oweis
The purpose of this study, accordingly, is to not only offer insights about Arab international students’ stress management and adjustment mechanisms while abroad but also bring to light the extent to which these digital citizens’ use of social media networks reinforces their citizenship values and preserves their national identity during the COVID-19 global health crisis.

Secondary Attack Rates for Omicron and Delta Variants of SARS-CoV-2 in Norwegian Households
Silje B. Jørgensen, MD, PhD; Karin Nygård, PhD; Oliver Kacelnik, MD, PhD; et al.
free access has active quiz
This nationwide registry data study from Norway assesses the secondary attack rate of SARS-CoV-2 variants Delta and Omicron in an effort to estimate the transmissibility of the Omicron variant.

Myocarditis Following a Third BNT162b2 Vaccination Dose in Military Recruits in Israel
Limor Friedensohn, MD; Dan Levin, MD; Maggie Fadlon-Dernai, MHA; et al.
free access has active quiz
This study assessed whether a third vaccine dose was associated with the risk of myocarditis among military personnel in Israel.

Viewpoint
Attacks on Health Care in the War in Ukraine: International Law and the Need for Accountability
Lawrence O. Gostin, JD; Leonard S. Rubenstein, JD
free access has audio
This Viewpoint from Gostin and Rubenstein examine the violence against health care workers and institutions in the war in Ukraine and potential paths to hold those perpetuating such attacks accountable.
Editorial

Catastrophic Health Consequences of the War in Ukraine
Phil B. Fontanarosa, MD, MBA; Annette Flanagin, RN, MA; Robert M. Golub, MD

Medical News & Perspectives

Clinical Trials Disrupted During War in Ukraine
Rita Rubin, MA
free access has audio
This Medical News feature describes how the Russian invasion has disrupted clinical trials in Ukraine as well as Russia.

JAMA Network

COVID-19 Update April 30, 2022
These articles on COVID-19 were published across the JAMA Network in the last week.

JAMA Pediatrics
April 2022, Vol 176, No. 4, Pages 335-428
https://jamanetwork.com/journals/jamapediatrics/currentissue
[Reviewed earlier]

JBI Evidence Synthesis
April 2022 - Volume 20 - Issue 4
https://journals.lww.com/jbisrir/Pages/currenttoc.aspx
[New issue; No digest content identified]

Journal of Adolescent Health
April 2022 Volume 70 Issue 4 p517-696
https://www.jahonline.org/current
[Reviewed earlier]

Journal of Artificial Intelligence Research
Vol. 73 (2022)
https://www.jair.org/index.php/jair
[Reviewed earlier]

Journal of Community Health
Volume 47, issue 2, April 2022
[Reviewed earlier]
Journal of Development Economics
Volume 156  May 2022
[Reviewed earlier]

Journal of Empirical Research on Human Research Ethics
Volume 17 Issue 1-2, February-April 2022
http://journals.sagepub.com/toc/jre/current
[Reviewed earlier]

Journal of Epidemiology & Community Health
April 2022 - Volume 76 - 4
https://jech.bmj.com/content/76/4
[Reviewed earlier]

Journal of Evidence-Based Medicine
Volume 15, Issue 1  Pages: 1-72  March 2022
https://onlinelibrary.wiley.com/toc/17565391/current
[Reviewed earlier]

Journal of Global Ethics
Volume 17, Issue 3, 2021
http://www.tandfonline.com/toc/rjge20/current
[Reviewed earlier]

Journal of Health Care for the Poor and Underserved (JHCPU)
Volume 33, Number 1, February 2022
https://muse.jhu.edu/issue/47329
Table of Contents
[Reviewed earlier]

Journal of Immigrant and Minority Health
Volume 24, issue 2, April 2022
[Reviewed earlier]

Journal of Immigrant & Refugee Studies
Volume 20, 2022 - Issue 1
https://www.tandfonline.com/toc/wimm20/current
[Reviewed earlier]
COVID-19 vaccines: awareness, attitude and acceptance among undergraduate University students
The myths and conspiracy theories on the COVID-19 vaccine cause people to be hesitant and maleficent towards the vaccine.
Authors: Firew Asres and Belachew Umeta
Citation: Journal of Pharmaceutical Policy and Practice 2022 15:32
Content type: Research Published on: 26 April 2022
Journal of Refugee & Global Health
Volume 4, Issue 1 (2021)
https://ir.library.louisville.edu/rgh/
[Reviewed earlier]

Journal of the Royal Society – Interface
April 2022 Volume 19 Issue 189
https://royalsocietypublishing.org/toc/rsif/current
[Reviewed earlier]

Journal of Travel Medicine
Volume 29, Issue 2, March 2022
https://academic.oup.com/jtm/issue
[Reviewed earlier]

Journal of Virology
Volume 96 Number 4 February 2022
http://jvi.asm.org/content/current
[Reviewed earlier]

The Lancet
Apr 30, 2022 Volume 399 Number 10336 p1669-1752, e39-e41
https://www.thelancet.com/journals/lancet/issue/current

Articles
Efficacy, safety, and immunogenicity of an inactivated, adjuvanted enterovirus 71 vaccine in infants and children: a multiregion, double-blind, randomised, placebo-controlled, phase 3 trial
Trong Toan Nguyen, et al.

Series
Optimising Child and Adolescent Health and Development
Health and development from preconception to 20 years of age and human capital
Robert E Black, et al.

Optimising Child and Adolescent Health and Development
Effects of early-life poverty on health and human capital in children and adolescents: analyses of national surveys and birth cohort studies in LMICs
Cesar G Victora, et al.

The Lancet Child & Adolescent Health
Apr 2022 Volume 6 Number 4 p215-278, e13-e15
https://www.thelancet.com/journals/lanchi/issue/current
**Nature**

**Volume 604 Issue 7907, 28 April 2022**

[https://www.nature.com/nature/volumes/604/issues/7907](https://www.nature.com/nature/volumes/604/issues/7907)

**Article** | 07 March 2022 | Open Access

**SARS-CoV-2 is associated with changes in brain structure in UK Biobank**

Gwenaëlle Douaud, Soojin Lee, Stephen M. Smith

After infection with SARS-CoV-2, individuals show a greater reduction in grey matter thickness and tissue contrast in the orbitofrontal cortex and parahippocampal gyrus; greater changes in markers of tissue damage in regions that are functionally connected to the primary olfactory cortex; and a greater reduction in global brain size.

**Article**

**Climate change increases cross-species viral transmission risk**

Colin J. Carlson, et al.

Published: 28 April 2022

Abstract

At least 10,000 virus species have the capacity to infect humans, but at present, the vast majority are circulating silently in wild mammals1,2. However, climate and land use change will produce novel opportunities for viral sharing among previously geographically-isolated species of wildlife3,4. In some cases, this will facilitate zoonotic spillover—a mechanistic link between global environmental change and disease emergence. Here, we simulate potential hotspots of future viral sharing, using a phylogeographic model of the mammal-virus network, and projections of geographic range shifts for 3,139 mammal species under climate change and land use scenarios for the year 2070. We predict that species will aggregate in new combinations at high elevations, in biodiversity hotspots, and in areas of high human population density in Asia and Africa, driving the novel cross-species transmission of their viruses an estimated 4,000 times. Because of their unique dispersal capacity, bats account for the majority of novel viral sharing, and are likely to share viruses along evolutionary pathways that will facilitate future emergence in humans. Surprisingly, we find that this ecological transition may already be underway, and holding warming under 2 °C within the century will not reduce future viral sharing. Our findings highlight an urgent need to pair viral surveillance and discovery efforts with biodiversity surveys tracking species’ range shifts, especially in tropical regions that harbor the most zoonoses and are experiencing rapid warming.

**Nature Biotechnology**

Volume 40 Issue 4, April 2022

[https://www.nature.com/nbt/volumes/40/issues/4](https://www.nature.com/nbt/volumes/40/issues/4)

[Reviewed earlier]

**Nature Communications**

[https://www.nature.com/subjects/health-sciences/ncomms](https://www.nature.com/subjects/health-sciences/ncomms)

(Accessed 30 Apr 2022)

[No new digest content identified]
New England Journal of Medicine
April 28, 2022  Vol. 386 No. 17
https://www.nejm.org/toc/nejm/medical-journal

Original Articles

Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting
O. Magen and Others

Review Article

Understanding Vaccine Safety and the Roles of the FDA and the CDC
H.C. Meissner
Editorials

Covid-19 Boosters — Where from Here?
P.A. Offit

On December 10, 2020, Pfizer presented results from a 36,000-person, two-dose, prospective, placebo-controlled trial of its Covid-19 messenger RNA (mRNA) vaccine, BNT162b2, to the Food and Drug Administration (FDA). The vaccine was 95% effective at preventing severe illness in all age groups, independent of coexisting conditions or racial or ethnic background. A remarkable result. Six months later, studies showed that protection against severe disease was holding up. The results of these epidemiologic studies were consistent with those of immunologic studies showing long-lived, high frequencies of Covid-19-specific memory B and T cells, which mediate protection against severe disease.

In September 2021, 10 months after the BNT162b2 vaccine had become available, Israeli researchers found that protection against severe illness in people 60 years of age or older was enhanced by a third dose. In response, the Centers for Disease Control and Prevention (CDC) recommended that people 65 years of age or older should receive three doses of an mRNA vaccine.

In a study now reported in the Journal, Israeli researchers found that in a study population with a median age of 72 years, protection against severe disease was further enhanced by a fourth dose of mRNA vaccine during the wave of infections caused by the B.1.1.529 (omicron) variant of SARS-CoV-2. These findings were considered by the FDA and CDC in their decision-making process regarding the use of an additional booster dose of mRNA vaccine for people 50 years of age or older.

What about booster dosing for persons who are younger? One year after the BNT162b2 vaccine became available, studies in the United States showed that a third dose of vaccine also enhanced protection against severe disease for people as young as 18 years of age. Unfortunately, these studies did not stratify patients according to whether they had coexisting conditions. Therefore, it was unclear who among these younger age groups most benefited from an additional dose. Nonetheless, the CDC later recommended that everyone 12 years of age or older should receive three doses of BNT162b2, regardless of whether risk factors were present. This universal booster recommendation led some summer camps, high schools, universities, hospitals, and businesses to require three doses of mRNA vaccine. In February 2022, in a study that did not support the booster recommendation for children, CDC researchers found that two doses of BNT162b2 induced long-lived protection against serious illness in children 12 to 18 years of age.

In addition to protection against severe disease, the initial phase 3 trial of BNT162b2 — which was performed over a period of several months — also showed 95% protection against mild illness. Unlike protection against severe illness, however, protection against mild illness, which is mediated by high titers of virus-specific neutralizing antibodies at the time of exposure, declined after 6 months, as would have been expected. In response, studies by Pfizer were published in which a booster dose was shown to restore protection against mild illness; unfortunately, this protection did not persist for more than a few months. Short-lived protection against mild illness will limit the ability of booster dosing to lessen transmission.

People are now confused about what it means to be fully vaccinated. It is easy to understand how this could happen. Arguably, the most disappointing error surrounding the use of Covid-19 vaccines was the labeling of mild illnesses or asymptomatic infections after vaccination as “breakthroughs.” As is true
for all mucosal vaccines, the goal is to protect against serious illness — to keep people out of the hospital, intensive care unit, and morgue. The term “breakthrough,” which implies failure, created unrealistic expectations and led to the adoption of a zero-tolerance strategy for this virus. If we are to move from pandemic to endemic, at some point we are going to have to accept that vaccination or natural infection or a combination of the two will not offer long-term protection against mild illness.

In addition, because boosters are not risk-free, we need to clarify which groups most benefit. For example, boys and men between 16 and 29 years of age are at increased risk for myocarditis caused by mRNA vaccines.\(^1\) And all age groups are at risk for the theoretical problem of an “original antigenic sin” — a decreased ability to respond to a new immunogen because the immune system has locked onto the original immunogen. An example of this phenomenon can be found in a study of nonhuman primates showing that boosting with an omicron-specific variant did not result in higher titers of omicron-specific neutralizing antibodies than did boosting with the ancestral strain.\(^1\) This potential problem could limit our ability to respond to a new variant.

It is now incumbent on the CDC to determine who most benefits from booster dosing and to educate the public about the limits of mucosal vaccines. Otherwise, a zero-tolerance strategy for mild or asymptomatic infection, which can be implemented only with frequent booster doses, will continue to mislead the public about what Covid-19 vaccines can and cannot do.

njp Vaccines
https://www.nature.com/npjvaccines/
[Accessed 30 Apr 2022]
Article
[No new digest content identified]

Pediatrics
Volume 149, Issue 4, April 1, 2022
https://pediatrics.aappublications.org/
[Reviewed earlier]

PharmacoEconomics
Volume 40, issue 3, March 2022
[Reviewed earlier]

PLoS Biology
https://journals.plos.org/plosbiology/
(Accessed 30 Apr 2022)
One step closer to a transmissible vaccine for rabies virus
Scott L. Nuismer
Primer | published 20 Apr 2022 PLOS Biology
https://doi.org/10.1371/journal.pbio.3001607
[No new digest content identified]

**PLoS Medicine**
https://www.plosmedicine.org/
(Accessed 30 Apr 2022)

*Nonregistration, discontinuation, and nonpublication of randomized trials: A repeated metaresearch analysis*
Research Article | published 27 Apr 2022 PLOS Medicine
https://doi.org/10.1371/journal.pmed.1003980

*Social justice now for an equitable tomorrow: Reflections from the Consortium of Universities for Global Health Conference 2022*
Beryne Odeny, Callam Davidson
Perspective | published 22 Apr 2022 PLOS Medicine
https://doi.org/10.1371/journal.pmed.1003995

**PLoS Neglected Tropical Diseases**
http://www.plosntds.org/
(Accessed 30 Apr 2022)
[No new digest content identified]

**PLoS One**
http://www.plosone.org/
(Accessed 30 Apr 2022)

*Age and sex associations of SARS-CoV-2 antibody responses post BNT162b2 vaccination in healthcare workers: A mixed effects model across two vaccination periods*
Cleo Anastassopoulou, Dimitra Antoni, Yiannis Manoussopoulos, Panagiotis Stefanou, Sofia Argyropoulou, Georgia Vrioni, Athanasios Tsakris
Research Article | published 29 Apr 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0266958
Human drone interaction in delivery of medical supplies: A scoping review of experimental studies
Franziska Stephan, Nicole Reinsperger, Martin Grünthal, Denny Paulicke, Patrick Jahn
Research Article | published 28 Apr 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0267664

Vaccination against misinformation: The inoculation technique reduces the continued influence effect
Mikołaj Buczel, Paulina D. Szyszka, Adam Siwiak, Malwina Szpitalak, Romuald Polczyk
Research Article | published 28 Apr 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0267463

Responsiveness of open innovation to COVID-19 pandemic: The case of data for good
Francesco Scotti, Francesco Pierri, Giovanni Bonaccorsi, Andrea Flori
Research Article | published 26 Apr 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0267100

PLoS Pathogens
http://journals.plos.org/plospathogens/
[Accessed 30 Apr 2022]
[No new digest content identified]

PNAS - Proceedings of the National Academy of Sciences of the United States
April 26, 2022 vol. 119 no. 17
[New issue; No digest content identified]

April 19, 2022 | vol. 119 | no. 16
https://www.pnas.org/toc/pnas/119/16
[New issue; No digest content identified]

Prehospital & Disaster Medicine
Volume 37 - Issue 2 - April 2022
https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue
[Reviewed earlier]

Preventive Medicine
Volume 157 April 2022
[Reviewed earlier]

Proceedings of the Royal Society B
13 April 2022 Volume 289 Issue 1972
**Vaccine Inequity and Hesitancy: A Vicious Cycle Undermining the Fight Against the COVID-19 Pandemic**

Gudina EK, Mekonnen Z, Yilma D
Risk Management and Healthcare Policy 2022, 15:865-869
Published Date: 29 April 2022

**Chinese University Students’ Awareness and Acceptance of the COVID-19 Vaccine: A Cross-Sectional Study**

Li S, Gao Z, Zhong M, Yu Z, Li J, Bi H
Risk Management and Healthcare Policy 2022, 15:845-864
Published Date: 29 April 2022

**COVID-19 in Veterans: A Narrative Review**

Chuang YC, Tsai HW, Liu SA, Wu MJ, Liu PY
Risk Management and Healthcare Policy 2022, 15:805-815
Published Date: 26 April 2022

*Science*

Volume 376| Issue 6592| 29 Apr 2022
https://www.science.org/toc/science/current

**A global system for the next generation of vaccines**

BY Nimalan Arinaminpathy, Chadi M. Saad-Roy, Qiqi Yang, Isa Ahmad, Prashant Yadav, Bryan Grenfell
28 Apr 2022: 462-464

**COVID-19 has shown that hurdles can be overcome**

The rapid development of vaccines against COVID-19 raises questions about what could be achieved in vaccines to other major diseases. Influenza presents an important case study; it is one of the few infections that causes substantial public health burden in its endemic form while also having proven pandemic potential. We offer a first step in bringing together the value proposition of future influenza vaccines considering two key characteristics: the breadth of protection that vaccines offer (against individual strains, all strains within a subtype, multiple subtypes, or all subtypes) and the duration for which protection remains effective (see the figure). We examine implications of these characteristics, from both epidemiologic and economic perspectives, and discuss how a future market for influenza vaccines might best align public health and economic incentives. Although many of these factors are
specific to influenza, we consider comparisons with other major infections, such as tuberculosis and COVID-19.

**Science and Engineering Ethics**
Volume 28, issue 2, April 2022
[link to journal]

*Original Research/Scholarship - Open Access*

**Standards of Conducts for Biostatisticians and Stem Cell Researchers: A Call for Self-formulated Aspirational Ethics Over Built-in Prohibitive Ethics**
Keiko Sato & Mika Suzuki
Published: 17 March 2022

*Abstract*
We proposed the Standards of Conducts to provide a general framework that will serve as the basis for guiding each biostatistician and stem cell researcher to formulate their personal standards, rather than as rules with which they are required to comply. Given the responsibility and characteristics of their work, they are expected to maintain independence and work autonomously as professionals. Each of the Standards of Conducts comprises a preamble, mission and values to uphold, Standards of Conducts (10 items), and background. When one internalizes “self-formulated” standards, to make excuses for oneself would be akin to a self-betrayal; responsible actions can be anticipated. If one begins and continues to consider “who I am and what do I work for,” this will become their inner energy, and a source of motivation and pride to inspire oneself. In addition, this aspirational style might help citizens to recognize the autonomous stance of the professional body and that they share the same values.

**Science Translational Medicine**
Volume 14| Issue 642| 27 Apr 2022
[link to journal]

[New issue; No digest content identified]

**Social Science & Medicine**
Volume 298  April 2022
[link to journal]

*Research article  Open access*

**Vaccine anxieties, vaccine preparedness: Perspectives from Africa in a Covid-19 era**
Melissa Leach, Hayley MacGregor, Grace Akello, Lawrence Babawo, ... Khoudia Sow
Article 114826

*Research article  Full text access*

**Applying an extended protection motivation theory to predict Covid-19 vaccination intentions and uptake in 50–64 year olds in the UK**
Bethany Griffin, Mark Conner, Paul Norman
Article 114819

*Research article  Abstract only*

**Vaccine discourse in white nationalist online communication: A mixed-methods computational approach**
The path towards herd immunity: Predicting COVID-19 vaccination uptake through results from a stated choice study across six continents
Stephane Hess, Emily Lancsar, Petr Mariel, Jürgen Meyerhoff, ... Mark H.P. Zuidgeest
Article 114800

Inside the ‘black box’ of COVID-19 vaccination beliefs: Revealing the relative importance of public confidence and news consumption habits
Jennifer A. Lueck, Timothy Callaghan
Article 114874

Strategies to overcome vaccine hesitancy: a systematic review
Vaccination, albeit a necessity in the prevention of infectious diseases, requires appropriate strategies for addressing vaccine hesitancy at an individual and community level. However, there remains a glaring...
Authors: Prem Singh, Pritu Dhalaria, Satabdi Kashyap, Gopal Krishna Soni, Partha Nandi, Shreeparna Ghosh, Mrinal Kar Mohapatra, Apurva Rastogi and Divya Prakash
Citation: Systematic Reviews 2022 11:78
Content type: Research Published on: 26 April 2022

Theoretical Medicine and Bioethics
Volume 43, issue 1, February 2022
https://link.springer.com/journal/11017/volumes-and-issues/43-1
[Reviewed earlier]

Travel Medicine and Infectious Diseases
Volume 46 March–April 2022
[Reviewed earlier]

COVID-19 vaccine acceptability among healthcare workers in Ethiopia: Do we practice what we preach?
Sociodemographic and psychological correlates of COVID-19 vaccine hesitancy and resistance in the young adult population in Italy
Ughetta Moscardino, Pasquale Musso, Cristiano Inguglia, Chiara Cecon, ... Cécile Rousseau
Pages 2379-2387

Public health facility quality and child immunization outcomes in rural India: A decomposition analysis
Amit Summan, Arindam Nandi, Emily Schueller, Ramanan Laxminarayan
Pages 2388-2398

Policy and practice of checking vaccination status at school in 2018, a global overview
Katrin Sadigh, Garrett Fox, Nino Khetsuriani, Hongjiang Gao, ... Kirsten Ward
Pages 2432-2441

COVID-19 vaccine intention among young adults: Comparative results from a cross-sectional study in Canada and France
Pierre-julien Coulaud, Aidan Ablona, Naseeb Bolduc, Danya Fast, ... Rod Knight
Pages 2442-2456

Public opinion on global distribution of COVID-19 vaccines: Evidence from two nationally representative surveys in Germany and the United States
Matthias Klumpp, Ida G. Monfared, Sebastian Vollmer
Pages 2457-2461
medRxiv is a free online archive and distribution server for complete but unpublished manuscripts (preprints) in the medical, clinical, and related health sciences. Preprints are preliminary reports of work that have not been certified by peer review. They should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information. medRxiv is for the distribution of preprints - complete but unpublished manuscripts - that describe human health research conducted, analyzed, and interpreted according to scientific principles...

**The impact of COVID-19 pandemic on influenza surveillance: a systematic review and meta-analysis**
Sasidharanpillai Sabeena, N Ravishankar, Sudandiradas Robin
medRxiv 2022.03.31.22273236; doi: https://doi.org/10.1101/2022.03.31.22273236 Revision

**Higher contact among vaccinated can be a mechanism for negative vaccine effectiveness**
Korryn Bodner, Jesse Knight, Mackenzie A. Hamilton, Sharmistha Mishra
medRxiv 2022.04.25.22274266; doi: https://doi.org/10.1101/2022.04.25.22274266 Revision

**Which countries need COVID-19 vaccines the most? Development of a prioritisation tool**
Vageesh Jain, Rifat Atun, Paul Hansen, Paula Lorgelly
medRxiv 2022.04.27.22274377; doi: https://doi.org/10.1101/2022.04.27.22274377

**A systematic review of the experiences of minority language users in health and social care research**
Dr Llinos Haf Spencer, Mrs Beryl Ann Cooledge, Dr Zoe Hoare
medRxiv 2022.04.27.22273307; doi: https://doi.org/10.1101/2022.04.27.22273307

**Real-world study of the effectiveness of BBIBP-CorV (Sinopharm) COVID-19 vaccine in the Kingdom of Morocco**
Yaowen Zhang, Jihane Belayachi, Yunkai Yang, Qiang Fu, Lance Rodewald, Hongling Li, Bing Yan, Ying Wang, Yanna Shen, Qian Yang, Weiyun Mu, Rong Tang, Chen Su, Tianfang Xu, Majdouline Obtel, Abdelkader Mhayi, Rachid Razine, Redouane Abouqal, Yuntao Zhang, Xiaoming Yang
medRxiv 2022.04.23.22274112; doi: https://doi.org/10.1101/2022.04.23.22274112

**Mondo: Unifying diseases for the world, by the world**
Monica C Munoz-Torres, Tristan H Nelson, Frank W Nicholas, David Ochoa, Daniel P Olson, Tudor I Oprea, David Osumi-Sutherland, Helen Parkinson, Zoë May Pendlington, Ana Rath, Heidi L Rehm, Lyubov Remennik, Erin R Riggs, Paola Roncaglia, Justyne E Ross, Marion F Shadbolt, Kent A Shefchek, Morgan N Similuk, Nicholas Sioutos, Damian Smedley, Rachel Sparks, Ray Stefancsik, Ralf Stephan, Andrea L Storm, Doron Stupp, Gregory S Stupp, Jagadish Chandrabose Sundaramurthi, Imke Tammen, Darin Tay, Courtney L Thaxton, Eloise Valasek, Jordi Valls-Margarit, Alex H Wagner, Danielle Welter, Patricia L Whetzel, Lori L Whiteman, Valerie Wood, Colleen H Xu, Andreas Zankl, Xingmin Aaron Zhang, Christopher G Chute, Peter N Robinson, Christopher J Mungall, Ada Hamosh, Melissa A Haendel

medRxiv 2022.04.13.22273750; doi: https://doi.org/10.1101/2022.04.13.22273750 Revision

Strengthening vaccination delivery system resilience in the context of protracted humanitarian crisis: a realist-informed systematic review
Sharif A. Ismail, Sze Tung Lam, Sadie Bell, Fouad M. Fouad, Karl Blanchet, Josephine Borghi
medRxiv 2022.04.21.22273340; doi: https://doi.org/10.1101/2022.04.21.22273340 Revision

Wellcome Open Research [to 30 Apr 2022]
https://wellcomeopenresearch.org/browse/articles
[Accessed 30 Apr 2022]
Wellcome Open Research provides all Wellcome researchers with a place to rapidly publish any results they think are worth sharing. All articles benefit from rapid publication, transparent peer review and editorial guidance on making all source data openly available.

Research Article metrics
Revised
What are the active ingredients of 'arts in health' activities? Development of the INgredients iN ArTs in hEalth (INNATE) Framework [version 2; peer review: 1 approved, 1 approved with reservations]
Katey Warran, Alexandra Burton, Daisy Fancourt
Peer Reviewers Gunter Kreutz; Melissa Forbes
Funders
Wellcome Trust
Leverhulme Trust
UK Research and Innovation
LATEST VERSION PUBLISHED 29 Apr 2022

Think Tanks

Brookings [to 30 Apr 2022]
http://www.brookings.edu/
Accessed 30 Apr 2022
Latest Research
Essay
Lessons learned from support to business during COVID-19
Lessons learned from expanded unemployment insurance during COVID-19
Peter Ganong, Fiona Greig, Pascal Noel, Daniel M. Sullivan, and Joseph Vavra
Wednesday, April 27, 2022

Lessons learned from the use of nontraditional data during COVID-19
Tomaz Cajner, Laura J. Feiveson, Christopher J. Kurz, and Stacey Tevlin
Wednesday, April 27, 2022

Lessons learned from support for the state and local sector during COVID-19
Louise Sheiner
Wednesday, April 27, 2022

Lessons learned from the COVID-19 policy response and child well-being
Anna Aizer and Claudia Persico
Wednesday, April 27, 2022

With the COVID-19 pandemic hitting government balance sheets especially hard in low-income countries, the World Bank’s shareholders—including the United States—agreed to an advance replenishment of its grant and low-interest loan window, the International Development Association (IDA). By holding a ...

COVID-19 has disrupted health systems across the globe. Nigeria reported its first COVID-19 case in February 2020, and, since then, the government has rolled out four vaccines to help control the pandemic—Moderna, Oxford-Astra Zeneca (AZ), Johnson & Johnson (J&J) and Pfizer-BioNTech.
COVID-19 radically changed most people’s lives in 2020, including across Africa. In Ethiopia, the disruption started with school closing, and other restrictions soon followed. Despite these efforts to contain the virus, Ethiopia—like almost all countries—suffered significant health impacts. It has r...

**Chatham House**  [to 30 Apr 2022]
https://www.chathamhouse.org/  
*Accessed 30 Apr 2022*  
[No new digest content identified]

**CSIS**  [to 30 Apr 2022]
https://www.csis.org/  
*Accessed 30 Apr 2022*  
**Transcript**  
**Equity in Immunization Services to Ensure “A Long Life for All”**  
April 29, 2022  

*Podcast Episode*  
**Covid, Ukraine, and the New Geopolitical Logic**  
April 28, 2022 | By *H. Andrew Schwartz, J. Stephen Morrison*

*Report*  
**Securing Medical Supply Chains with Trusted Trade Partners**  
April 29, 2022 | *Meredith Broadbent*  
A new report from CSIS assesses the potential of nearshoring medical supply chains to neighbors in the Americas, using the case studies of Canada, Brazil, Mexico, and Colombia.

**Kaiser Family Foundation**  
https://www.kff.org/search/?post_type=press-release  
*Accessed 30 Apr 2022*  
*Accessed 30 Apr 2022*  
[No new digest content identified]

**ODI [Overseas Development Institute]**  [to 30 Apr 2022]
*Publications*  
*Accessed 30 Apr 2022*  
[No new digest content identified]

**Rand**  [to 30 Apr 2022]
https://www.rand.org/pubs.html  
*Reports, Selected Journal Articles*  
*Report*
A Risk Assessment of National Critical Functions During COVID-19: Challenges and Opportunities

This report presents a framework for assessing risk that the coronavirus disease 2019 (COVID-19) poses to the National Critical Functions, describes challenges in implementing the framework, and provides recommendations for improving it.

Apr 26, 2022
Andrew Lauland, Benjamin Lee Preston, Kristin J. Leuschner, Michelle E. Miro, Liam Regan, Scott R. Stephenson, Rachel Steratore, Aaron Strong, Jonathan W. Welburn, Jeffrey B. Wenger

Urban Institute  [to 30 Apr 2022]
https://www.urban.org/publications
Research Publications
Brief
COVID-19 and the System Resilience of Public Education: A View from North Carolina
April 28, 2022

* * * * *
* * * *

Vaccines and Global Health: The Week in Review is a service of the Center for Vaccine Ethics and Policy (CVEP)/GE2P2 Global Foundation, which is solely responsible for its content.

:::::::

Copyright GE2P2 Global Foundation 2022. Some Rights Reserved.

This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.

Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation The Rockefeller foundation, Boston University, or 3-D Commission logos is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.

:::::::

CVEP is a program of the GE2P2 Global Foundation whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.
Support for this service is provided by the Bill & Melinda Gates Foundation; the Bill & Melinda Gates Medical Research Institute, PATH, and industry resource members Janssen/J&J, Pfizer and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.